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The salt-inducible kinases, SIK1, SIK2 and SIK3, most closely resemble the AMP-acti-
vated protein kinase (AMPK) and other AMPK-related kinases, and like these family
members they require phosphorylation by LKB1 to be catalytically active. However, unlike
other AMPK-related kinases they are phosphorylated by cyclic AMP-dependent protein
kinase (PKA), which promotes their binding to 14-3-3 proteins and inactivation. The most
well-established substrates of the SIKs are the CREB-regulated transcriptional co-activa-
tors (CRTCs), and the Class 2a histone deacetylases (HDAC4/5/7/9). Phosphorylation by
SIKs promotes the translocation of CRTCs and Class 2a HDACs to the cytoplasm and
their binding to 14-3-3s, preventing them from regulating their nuclear binding partners,
the transcription factors CREB and MEF2. This process is reversed by PKA-dependent
inactivation of the SIKs leading to dephosphorylation of CRTCs and Class 2a HDACs and
their re-entry into the nucleus. Through the reversible regulation of these substrates and
others that have not yet been identified, the SIKs regulate many physiological processes
ranging from innate immunity, circadian rhythms and bone formation, to skin pigmenta-
tion and metabolism. This review summarises current knowledge of the SIKs and the evi-
dence underpinning these findings, and discusses the therapeutic potential of SIK
inhibitors for the treatment of disease.
Introduction
The AMP-activated protein kinase (AMPK) is one of the most studied protein kinases, the huge inter-
est in this enzyme stemming from the discovery that it is a key sensor of cellular energy charge and
one of the intracellular targets of metformin (also called glucophage), the drug used most commonly
to treat Type 2 diabetes [1–3]. For this reason, interest in AMPK has tended to overshadow the other
members of the same subfamily, which are equally interesting and are collectively termed the
AMPK-related kinases. Here, we begin to rectify this anomaly by reviewing current knowledge of the
salt-inducible kinases (SIKs). The first member was identified over 20 years ago when rats fed on a high
salt diet were found to induce a protein kinase in adrenal cortical tissue [4], initially termed SIK, but
later SIK1 when two other protein kinases with closely related catalytic domains were identified, which
are now called SIK2 (previously called QIK) and SIK3 (previously QSK) [5,6]. The mRNA encoding
SIK1 is not only induced by a high dietary salt intake [4], but also by adrenocorticotropic hormone
[4,7], circadian rhythms [8], glucagon signalling [9] and membrane depolarisation [10]. In contrast,
SIK2 and SIK3 are expressed constitutively in many tissues and ligands that increase or decrease their
level of expression have not been identified, although a recent paper reported that the expression of
these isoforms is reduced in adipose tissue from insulin-resistant or obese individuals [11].
In this review, we provide an overview of current knowledge about the SIKs, their physiological
roles and how they are regulated, highlighting the potential therapeutic benefits that SIK inhibitors
may have for the treatment of a number of diseases.
Evolution of the SIKs
There is only one gene encoding an SIK in the nematode C.elegans, termed KIN-29, which is an
orthologue of mammalian SIK2 [12], whereas the fruit fly Drosophila melanogaster expresses both
SIK2 and SIK3 [13], indicating that the genes encoding these SIK isoforms arose during invertebrate
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evolution. In contrast, all vertebrates from fish to mammals express all three SIK isoforms. Strikingly, the genes
encoding sik2 and sik3 are located on the same chromosome in nearly all vertebrates whose genes have been
sequenced. In mice, the genes encoding SIK2 and SIK3 are located on chromosome 9 and in humans on
chromosome 11, where they are separated by only 4.6 Mb and 5.1 Mb, respectively. The gene encoding SIK1 is
located on a separate chromosome, which is chromosome 17 in mice and chromosome 21 in humans. The
reason for such close linkage of the genes encoding SIK2 and SIK3, which has been conserved through verte-
brate evolution, is unclear but it may permit the transcription of these genes to be regulated co-ordinately.
Interestingly, a recent duplication of the gene encoding SIK1 has occurred in humans creating an additional
SIK family member, termed SIK1B, which like the gene encoding SIK1 is located on chromosome 21. The
amino acid sequence of SIK1B is identical to that of SIK1, except for the replacement of Ala615 in SIK1 by Val
in SIK1B.
Phosphorylation and domain structure of the SIKs
Activation of SIKs by LKB1-dependent phosphorylation
All three SIKs have an N-terminal protein kinase domain, followed by a ubiquitin-associated (UBA) domain
and then a long C-terminal tail devoid of any recognisable structural feature (Figure 1A). Phosphorylation of a
threonine residue in the activation loop of each SIK (Thr182 in SIK1, Thr175 in SIK2 and Thr221 in SIK3) is
required for catalytic activity (Figure 1B). The mutation of these residues to Ala inactivates the SIKs [14] and
has been used to generate knock-in mice expressing kinase-inactive mutants of each SIK isoform [15]. The
protein kinase responsible for phosphorylating the activating threonine residues of SIKs in vivo, and indeed all
the other 13 AMPK-related kinases, apart from MELK, is liver kinase B1 (LKB1) [14]. The critical role of
LKB1 has been established by the absence of significant SIK activity in cells lacking LKB1 activity and expres-
sion, such as HeLa cells [14,16] or cells from LKB1 knock-out (KO) mice [14,17]. LKB1 is complexed with two
other proteins in cells, MO25 and STRADα or STRADβ. The binding of STRAD and MO25 localises LKB1 to
the cytosol and activates its kinase domain. This explains why LKB1 is constitutively active and hence why the
SIKs are tonically active in cells. Although phosphorylation of the threonine residue in the activation loop of
AMPK can be catalysed by calmodulin-dependent protein kinase kinase (CaMKK), and this mechanism oper-
ates to regulate AMPK in the central nervous system and in T cells [18], the SIKs are not activated in response
to stimulation with a calcium ionophore or by overexpression of CaMKK2 in HeLa cells [19].
SIK1 and SIK2, but not SIK3, are reported to undergo autophosphorylation in mammalian cells at Ser186
and Ser179, respectively [20], which are located four amino acids C-terminal to the activating phospho-
threonine residue (Figure 1B). This creates a consensus motif (TxxxS*, where x is any amino acid and S* is the
phosphorylation site) for phosphorylation by glycogen synthase kinase 3 (GSK3) [21], which may permit GSK3
to phosphorylate Thr182 of SIK1 and Thr175 of SIK2, creating a positive feedback loop to ensure the activation
of SIK1 and SIK2 is complete. This is an attractive hypothesis, but further experiments are needed to establish
whether this occurs in vivo. In particular, it needs to be established whether Ser186 and Ser179 are phosphory-
lated to a significant stoichiometry in the endogenous SIK1 and SIK2 proteins, and whether SIK1/2 activity
and Thr182/Thr175 phosphorylation are reduced in GSK3α and/or GSK3β KO cells, or in cells treated with
specific GSK3 inhibitors, such as CHIR99021 [22]. It should also be noted that Ser186 and Ser179 of SIK1 and
SIK2 are followed by a proline residue (Figure 1B), and do not conform to the preferred consensus sequence
for phosphorylation by SIKs and other AMPK-related kinases, which is LxB(S/T)xS*xxxL (where B is a basic
amino acid, x is any amino acid and S* is the site of phosphorylation) [5,23,24]. Ser186 and Ser179 might not
therefore be sites of autophosphorylation but phosphorylated by one or more members of the CMGC subfam-
ily of protein kinases that phosphorylate Ser/Thr-Pro sequences and which might have been trace contaminants
in the SIK1 and SIK2 immunoprecipitates used to study ‘autophosphorylation’ in these experiments. This pos-
sibility should be investigated using one or more of the relatively specific and structurally unrelated SIK inhibi-
tors that have now become available.
Inhibition of the SIKs by cyclic AMP-dependent protein kinase
In addition to the activating phosphorylation site(s) in the kinase catalytic domain, the C-terminal tails of the
SIKs are phosphorylated by cyclic AMP-dependent protein kinase (PKA) (Figure 1A). Two serine residues in
SIK1, four in SIK2 and three in SIK3 undergo phosphorylation by PKA in vitro [25], and in response to
physiological or pharmacological stimuli that elevate intracellular levels of cyclic AMP (Table 1) [26–30]. These
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cyclic AMP-elevating stimuli induce the dephosphorylation of physiological substrates of the SIKs [28–31],
indicating that phosphorylation by PKA inhibits SIK catalytic activity. However, a decrease in SIK activity
induced by PKA-catalysed phosphorylation in vitro has not yet been demonstrated with any SIK isoform
[27,28]. On the other hand, it has been shown that phosphorylation by PKA permits the SIKs to interact with
14-3-3 proteins (Figure 2). The phosphorylation of SIK1 at Thr473 and Ser575 drives the re-localisation of
A
B
Figure 1. Domain structure of the SIKs and sites of regulatory phosphorylation.
(A) Schematic of the domain structures of human SIK1 (Uniprot P57059), SIK2 (Q9H0K1) and SIK3 (Q9Y2K2) showing the
threonine in the N-terminal kinase domain phosphorylated by LKB1 (green), the ubiquitin-associated (UBA) domain and the
C-terminal tail with the sites of phosphorylation by PKA (red). The equivalent phosphorylation sites in murine SIK1 (Q60670) are
Thr182, Thr475 and Ser577; the equivalent phosphorylation sites in murine SIK2 (Q8CFH6) are Thr175, Ser343, Ser358, Thr484
and Ser587 and the equivalent phosphorylation sites in murine SIK3 (Q6P4S6) are Thr163, Thr411, Ser493 and Ser616.
(B) Alignment of the activation loop sequences of human AMPK-related kinases. Marked are the Thr phosphorylated by LKB1
and the conserved Ser at +4 reported to be a site of autophosphorylation. Identical residues are shaded in black and
conserved residues are shaded in grey. (C) As in B except that the gatekeeper Thr residue is marked.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1379








K user on 19 April 2021
SIK1 to the cytosol and binding to 14-3-3 proteins [25,30,32]. In contrast, SIK2 and SIK3 are localised predom-
inantly within the cytoplasm. PKA-dependent phosphorylation does not therefore induce the nucleo/cytoplas-
mic shuttling of SIK2 and SIK3 but, instead, phosphorylation of SIK2 at Ser343/Ser358 and Thr484/Ser587
generates two pairs of 14-3-3 binding sites [27,30] and the phosphorylation of SIK3 at Thr469 and Ser551 gen-
erates one 14-3-3 binding site [26,30]. It is therefore possible that the binding of 14-3-3s to the
PKA-phosphorylated forms of SIKs is required for their inactivation. Evidence in support of this hypothesis
was obtained in an experiment in which HEK293 cells were stimulated with forskolin, a cyclic AMP-elevating
agonist, and the SIK2 bound to 14-3-3s was immunoprecipitated from the cell extracts and assayed with a
peptide substrate. The activity of SIK2 was found to be partially reduced, compared with SIK2[Ser358Ala/
Ser587Ala] which did not co-immunoprecipitate with 14-3-3 [30]. Although more definitive experiments still
need to be performed, this would be analogous to the mechanism by which plant nitrate reductase is inacti-
vated in the dark, the first functional role for 14-3-3s to be identified [33]. The LKB1-dependent phosphoryl-
ation of SIK1 and SIK3 has also been reported to create a 14-3-3 binding site [34] and may underlie the low
level of 14-3-3 binding observed in cells not exposed to cyclic AMP-elevating agents; however there is a sub-
stantial increase in 14-3-3 binding to SIK1, SIK2 and SIK3 detected following PKA-dependent phosphorylation
[26,27,30].
In murine cortical neurons the expression of SIK2 was reported to be decreased during deprivation of
oxygen and glucose and was blocked by KN93, an inhibitor of calmodulin-dependent protein kinases 1 and 4
(CaMK1, CaMK4). CaMK1 and CaMK4 were also reported to phosphorylate SIK2 at Thr484 when overex-
pressed in neurons [35]. Phosphorylation of SIK1 in kidney cells was blocked by KN93 and SIK1 was phos-
phorylated on Thr322 by CaMK1 in vitro [36]. Additional phosphorylation sites have been detected at the
N-terminal end of the kinase domain and within the C-terminal tail of SIK2 and SIK3 in phospho-proteomic
screens [37–40]. In summary, the SIKs may be regulated by phosphorylation at other sites by kinases distinct
from PKA, LKB1 or the SIKs themselves, but more detailed investigation is needed to assess whether this is the
case and the potential significance of these findings.
The UBA domain of SIKs
Interestingly, ten AMPK-related kinases, including the SIKs, possess UBA domains and, indeed, they are the
only protein kinases encoded in the human genome that possess this domain [41]. In other proteins UBA
domains form ubiquitin or poly-ubiquitin binding motifs. However, despite conservation of the critical residues
(Gly316, Leu326, Tyr338, Leu340 and Leu341 in SIK1) needed to form the hydrophobic interface required for
Table 1 Amino acid sequences surrounding the Ser/Thr
residues in SIK1, SIK2 and SIK3 that are phosphorylated
by PKA
SIK Phosphorylation site Sequence
SIK1 Thr473 STGRRH T* LAEVST
SIK1 Ser575 QEGRRA S* DTSLTQ
SIK2 Ser343 LKSHRS S* FPVEQR
SIK2 Ser358 GRQRRP S* TIAEQT
SIK2 Thr484 SGQRRH T* LSEVTN
SIK2 Ser587 REGRRA S* DTSLTQ
SIK3 Thr469 LSMRRH T* VGVADP
SIK3 Ser551 PLGRRA S* DGGANI
SIK3 Ser626 SPVRRF S* DGAASI
S* and T* indicate the phosphorylated amino acid residues. Basic
amino acid residues N-terminal to the sites of phosphorylation are
highlighted in boldface type. All the phosphorylation sites lie in BBxS*/
T* sequences that conform to the classical consensus sequence for
phosphorylation by PKA (where B denotes any basic residue, most
frequently Arg) [135].
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1380
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ubiquitin binding, no interaction of Lys48-linked or Lys63-linked ubiquitin oligomers to either the UBA
domains of SIK1, SIK2 or SIK3 or the full length proteins was detected [42]. Although binding to other ubiqui-
tin species has not been reported, it currently seems that the main function of the UBA domain is to facilitate
the LKB1-dependent phosphorylation of the activation loop threonine residue [42]. It is not yet clear how the
UBA domain interacts with and alters the conformation of the kinase domain to allow phosphorylation by
LKB1 to occur. A high resolution three-dimensional structure of an SIK isoform will be needed to understand
this problem.
Physiological substrates of the SIKs
Two important groups of substrates for the SIKs have been identified, namely the cyclic
AMP-response-element binding protein (CREB)-regulated transcriptional co-activators (CRTC1, CRTC2 and
CRTC3) and the Class 2a histone deacetylases (HDAC4, HDAC5, HDAC7 and HDAC9) (Table 2).
Phosphorylation by SIKs induces the binding of CRTC family members to 14-3-3 proteins (Figure 2 and
Table 2) in the cytosol from where they are unable to activate the transcription factor CREB in the nucleus.
The inhibition of SIKs, either by PKA-dependent phosphorylation or pharmacological inhibition, allows the
rapid dephosphorylation of CRTCs, their translocation to the nucleus and binding to CREB, thereby promoting
CREB-dependent gene transcription (Figure 2) [17,23,43–46]. In addition, PKA can directly phosphorylate
A
B
Figure 2. Consequences of the activation and inactivation of the SIKs by phosphorylation.
(A) SIKs (orange) are activated by LKB1-dependent phosphorylation (green P) and phosphorylate (P) CRTC family members
and Class 2a HDACs (HDAC4/5/7/9). These phosphorylated substrates (light blue) bind to 14-3-3s which retains them in the
cytosol. (B) The SIKs are phosphorylated by PKA-dependent phosphorylation (red P) inducing binding to 14-3-3 proteins (dark
blue) and inactivation. PKA-dependent phosphorylation may also promote SIK1 translocation from the nucleus to the
cytoplasm (not shown). Inactivation of SIKs leads to the dephosphorylation and nuclear translocation of CRTCs and Class 2a
HDACs. Within the nucleus CRTCs promote (green +) CREB-dependent gene transcription and Class 2a HDACs inhibit (red X)
MEF2-dependent transcription.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1381
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CREB at Ser133 to stimulate the transcription of CREB-dependent genes. However, CREB-dependent transcrip-
tion of a subset of genes is still observed in cells in which endogenous CREB is replaced by the CREB
[Ser133Ala] mutant [47]. It would therefore appear that PKA can activate CREB-dependent gene transcription
via either or both of two mechanisms; phosphorylation and inhibition of SIKs and direct phosphorylation of
CREB.
Phosphorylation of Class 2a HDACs by SIKs promotes 14-3-3 binding (Table 2) and the retention of
HDACs in the cytosol. When SIKs are inactive, the Class 2a HDACs are dephosphorylated and translocate to
the nucleus where they bind to myocyte enhancer factor 2 (MEF2) and repress MEF2-dependent gene tran-
scription (Figure 2) [31,44,48,49]. It is currently thought that the Class 2a HDACs have little or no deacetylase
activity but instead act as adaptors by recruiting Class 1 HDACs and other chromatin modifiers to transcription
factor binding sites via interaction with MEF2 and other transcription factors [50,51]. Although phosphoryl-
ation by SIKs prevents the interaction of Class 2a HDACs with MEF2, it is unclear whether Class 2a HDACs
are inactive in the cytosol or whether they have other cytosolic functions. For example, cytoplasmic HDAC4 is
reported to promote vascular calcification through interaction with the cytoskeleton-associated protein
ENIGMA in vascular smooth muscle cells [52].
Development and exploitation of small molecule SIK
inhibitors
A number of SIK inhibitors are now available and have been widely used to study the physiological roles of
these protein kinases. It is therefore important to understand the caveats in the use of these reagents arising
from their imperfect selectivity. The compound MRT67307 (Figure 3) was originally developed as a potent
inhibitor of the IκB kinase (IKK)-related kinases TBK1 and IKKε [53]. Subsequently, it was found to enhance
the secretion of the anti-inflammatory cytokine interleukin (IL)-10 and to suppress the production of
pro-inflammatory cytokines in lipopolysaccharide (LPS)-stimulated monocytes and macrophages, which led to
the discovery that these effects were mediated by inhibition of the SIKs [17]. The closely related compound
MRT199665 (Figure 3) is an equally potent inhibitor of the SIKs, which does not inhibit TBK1 and IKKε, and
is therefore an improved version of MRT67307 [17,54]. However, while MRT199665 is a relatively specific SIK
inhibitor it also inhibits other AMPK-related kinases, and for this reason should be used in conjunction with
HG-9-91-01 (Figure 3); the latter is a structurally unrelated SIK inhibitor that does not inhibit any other
AMPK-related kinase family member [17].
Table 2 Sites on CRTCs and Class 2a HDACs phosphorylated by the SIKs
Substrate Phosphorylation site Sequence Reference
CRTC1 Ser151 SWRRTN S* DSALHQ [16]
CRTC2 Ser171 ALNRTS S* DSALHT [16,23]
CRTC2 Ser274 AMNTGG S* LPDLTN [44]
CRTC3 Ser62 TQYHGG S* LPNVSQ [17]
CRTC3 Ser162 ALNRTN S* DSALHT [17,44]
CRTC3 Ser273 TLNTGG S* LPDLTN [45]
CRTC3 Ser329 GLQSSR S* NPSIQA [17]
CRTC3 Ser370 LRLFSL S* NPSLST [17]
HDAC4 Ser246 PLRKTA S* EPNLKL [31,44]
HDAC4 Ser467 PLGRTQ S* APLPQN [31]
HDAC5 Ser259 PLRKTA S* EPNLKV [31]
HDAC5 Ser498 PLSRTQ S* SPLPQS [31]
The Ser phosphorylated by SIKs lie in S*xP sequences (where S* indicates the phosphorylated
amino acid residue), which is one of the consensus sequences for interaction with 14-3-3 binding
proteins [136].
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1382
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The reason why HG-9-91-01 inhibits the SIK isoforms but does not inhibit any other AMPK-related kinases,
is because SIKs are unique among these family members in possessing an amino acid with a small side chain
(threonine) at the gatekeeper site (Figure 1C), which creates a small hydrophobic pocket near to the
ATP-binding site that is targeted by HG-9-91-01. Importantly, the mutation of this threonine to an amino acid
with a larger side chain generates SIK mutants with the same activity as the wild-type enzyme, but which are
resistant to inhibition by HG-9-91-01 [17]. The inducible overexpression of such mutants has been exploited to
investigate whether particular effects of HG-9-91-01 in cells are caused by SIK inhibition or by a non-specific
‘off-target’ effect of this compound. We therefore recommend that two structurally unrelated SIK inhibitors be
used routinely in cell-based studies, such as MRT199665 and HG-9-91-01, and wherever possible should also
be used in combination with a drug-resistant SIK mutant or with SIK-deficient cells or cells expressing
kinase-inactive mutants of SIKs. Such studies should identify physiological substrates and functions of the
SIKs, more reliably than the deployment of just a single SIK inhibitor by itself. This should be born in mind
when evaluating the sections that follow.
Figure 3. Chemical structures of compounds inhibiting SIKs.
Chemical structures of compounds inhibiting SIKs at low nM concentrations that have been used to study the functions of
SIKs in cells and in vivo. KIN-112, HG-9-91-01, YKL-05-099, YKL-06-061, YKL-06-062, Dasatinib and Bosutinib target the
gatekeeper site on SIKs (Figure 1C) whereas MRT67307 and MRT199665 do not. *Pterosin B treatment mimics several effects
of SIK3 KO in hepatocytes and chondrocytes but is not thought to be a direct inhibitor of SIK3.
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1383
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Although HG-9-91-01 is useful for studies of SIK function in isolated cells in vitro, its pharmacokinetic
properties are unsuitable for in vivo studies. For this reason, YKL-05-099 (Figure 3) an analogue of
HG-9-91-01 with superior pharmacokinetic characteristics has been developed to assess the in vivo roles of
SIKs [55]. Two further compounds, YKL-06-061 and YKL-06-062 (Figure 3), have been developed to optimise
their lipophicity and molecular size for topical use [56].
Like the SIKs, many protein tyrosine kinases contain a threonine residue at the gatekeeper site and most of
the compounds developed as inhibitors of tyrosine kinases, including many drugs approved for the treatment
of cancers (Cohen P., Cross D.R. and Jänne P. 2021 Nat Rev Drug Disc in press), target the hydrophobic
pocket created by the gatekeeper threonine. Indeed HG-9-91-01 is a more soluble derivative of KIN112
(Compound 28 in [57]), which was originally developed as an inhibitor of lymphocyte cell-specific protein-
tyrosine kinase (Lck), a member of the sarcoma kinase (Src) family of protein tyrosine kinases. HG-9-91-01 is
also a potent inhibitor of Src family members and other tyrosine and serine/threonine kinases with threonine
at the gatekeeper site [17]. Conversely, Dasatinib and Bosutinib, which are pan protein tyrosine kinase inhibi-
tors approved for the treatment of chronic myelogenous leukaemia, are potent inhibitors of the SIKs, and SIK
inhibition is likely to underlie the anti-inflammatory effects of Dasatinib [58].
In summary, the SIK inhibitors in current use have limitations and additional structurally unrelated SIK
inhibitors with enhanced specificity are needed, including compounds selective for particular SIK isoforms.
Compounds that may have improved specificity, such as ARN-3236 (Figure 3) are beginning to emerge now
that interest in targeting SIKs for the treatment of disease is increasing (see SIK-inhibiting drugs for the treat-
ment of disease).
Physiological roles of the SIKs
The role of SIKs in regulating macrophage function
The innate immune system is carefully balanced between a pro-inflammatory state, which is critical for the
clearance of infection, and an anti-inflammatory state that is required to stabilise and protect tissues in the
absence of infection and to aid tissue repair after infection. Macrophages are important because they have the
potential to produce both pro-inflammatory and anti-inflammatory cytokines during pathogenic infection. A
distinct profile of cytokines is secreted from macrophages depending on which pattern recognition receptor
(PRR) is activated and what other inputs a macrophage receives. For example, bone marrow-derived macro-
phages (BMDM) can be induced to secrete high levels of the pro-inflammatory cytokines TNF and interleukin
IL-12 if stimulated by bacterial LPS, but secrete high levels of the anti-inflammatory cytokine IL-10 in response
to both LPS and cyclic AMP-elevating ligands, such as prostaglandin E2 (PGE2) [59,60]. The synthesis and
secretion of PGE2 is itself driven by the LPS-stimulated induction of cyclooxygenase 2, the enzyme that cata-
lyses the rate-limiting step in the synthesis of prostaglandins [61].
While ligation of Toll-Like Receptor 4 by LPS alone leads to activation of the transcription factors required
for pro-inflammatory cytokine production, such as NF-κB and IRF5 [62], the combined stimulation with LPS
and PGE2 is required for the production and secretion of high levels of the anti-inflammatory cytokine IL-10.
Inhibition of the SIKs mediated by PKA-dependent phosphorylation (Figure 1A and Table 1) in response to
PGE2, leads to the dephosphorylation of CRTC3 and its translocation to the nucleus, where it promotes
CREB-dependent transcription of IL-10 in BMDM (Figure 2) [17,29], explaining why combined stimulation by
LPS and PGE2 is needed for high levels of IL-10 production. In one report, the siRNA knock-down of CRTC3
in BMDM was sufficient to block PGE2 or SIK inhibitor-induced IL-10 expression, and the knock-down of
CRTC1 and CRTC2 had no effect [17,29], while another laboratory reported that LPS and PGE2-stimulated
IL-10 expression was suppressed in either CRTC3 KO or CRTC2 KO BMDM [63]. The reason for this discrep-
ancy is unclear but might be related to differences in ligand concentrations used or the ways in which the
macrophages were differentiated. Studies with macrophages from a variety of knock-in mice in which each SIK
was replaced by a kinase-inactive mutant established that SIK2 and SIK3 activity is critical for the production
of IL-10 in foetal liver-derived macrophages [15].
Incubation with ‘pan’ SIK inhibitors suppressed the secretion of the pro-inflammatory cytokines TNF and
IL-12 in BMDM [17], in bone marrow-derived dendritic cells [64] or human myeloid cells [65]. Similarly,
LPS-stimulation of BMDM derived from knock-in mice expressing kinase-inactive mutants of each SIK
isoform induced lower secretion of TNF, IL-12 and IL-6 than in wild-type BMDM. LPS-stimulated
pro-inflammatory cytokine production was completely suppressed in foetal liver-derived macrophages from
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1384
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mice expressing kinase-inactive forms of both SIK2 and SIK3 [15]. The molecular mechanism by which SIKs
stimulate the production of pro-inflammatory cytokines is unknown. However, it has been reported that SIK
inhibition permits the dephosphorylation of HDAC4 and its translocation into the nucleus where it is proposed
to bind to and promote the de-acetylation of the p65 subunit of NF-κB at Lys310, preventing NF-κB from
binding to the tnf and il12β promoters [63]. Indeed, the suppression of LPS-stimulated secretion of
pro-inflammatory cytokines by PGE2 was blocked in HDAC4 KO BMDM and the occupancy of p65 at the
relevant promoters was restored [63]. The overexpression of the p65[Lys310Arg] mutant impaired
NF-κB-dependent gene transcription in transfected HEK293T cells [66]. In summary, further research is
required to determine whether HDAC4 directly de-acetylates p65, as de-acetylation of p65 has previously been
attributed to Class 1 HDACs [67–69]. Further work is also needed to establish whether de-acetylation of p65 at
Lys310 underlies the decrease in pro-inflammatory cytokine gene transcription detected in BMDM in response
to SIK inhibition. The generation of a conditional knock-in mouse expressing the p65[Lys310Arg] mutant may
be needed to establish this important point definitively.
The role of SIKs in regulating mast cell function
Recently a role for SIKs in promoting the secretion of cytokines from mast cells has been identified. Like
macrophages, mast cells are also innate immune cells, found in barrier tissues such as the gut, skin and lungs.
Epithelial cells in these tissues release IL-33 in response to cell damage or necrosis, stimulating mast cells to
release cytokines and chemokines. Treatment with two structurally unrelated pan-SIK inhibitors suppressed the
secretion of multiple cytokines including IL-13, granulocyte-macrophage colony stimulating factor (GM-CSF)
and TNF and chemokines including (C-C motif ) ligand 2 (CCL2, also known as monocyte chemoattractant
protein-1), CCL3 (macrophage inflammatory protein-1α), CCL4 (macrophage inflammatory protein-1β) and
CCL24 (eotaxin-2). Secretion of IL-13, GM-CSF and TNF was partially suppressed in mast cells expressing the
kinase-inactive SIK3[Thr163Ala] mutant or in SIK3 KO mast cells and was abolished in mast cells from SIK2
[Thr175Ala]/SIK3[Thr163Ala] kinase-inactive double knock-in or SIK2/3 double KO mice. On the other hand,
secretion of these cytokines was little affected in mast cells expressing SIK1[Thr182Ala]/SIK2[Thr175Ala]
kinase-inactive double knock-in or in SIK2 KO mast cells. The lack of any effect on cytokine production in
SIK2 KO mast cells may be explained by the greatly increased expression of SIK3 in these cells. The
IL-33-dependent secretion of chemokines was also abolished in SIK2/3 double KO mast cells [54]. In summary
SIK2 and SIK3 play a critical role in mediating the IL-33 stimulated secretion of cytokines and chemokines in
mast cells, however the underlying molecular mechanisms have yet to be defined.
The role of SIKs in regulating bone formation; implications for osteoarthritis
and osteoporosis
Bone development and bone remodelling are both regulated by the peptide hormones, parathyroid hormone
(PTH) and parathyroid hormone-related peptide (PTHrP), which also act to maintain mineral ion homeostasis.
PTH and PTHrP are recognised by the PTH1 receptor, a transmembrane G protein-coupled receptor. As sig-
nalling via the PTH1 receptor promotes bone formation, there is considerable interest in manipulating this
pathway in a therapeutic setting and indeed, PTH1 receptor agonists are currently used to treat osteoporosis
[70]. Within bone, osteocytes express the highest copy numbers of the PTH1 receptor and are the most abun-
dant cell type [71]. Stimulation of osteocytes in cell culture with PTH drives the activation of PKA and subse-
quent phosphorylation of SIK2, but apparently not SIK3 [72]. In osteocytes, activation of the PTH signalling
pathway drives the CREB-dependent expression of receptor activator of NF-κB ligand (RANKL) [73] which
acts on osteoblasts and osteocytes to promote bone resorption [74]. As anticipated, KO or knock-down of SIK2
in osteocytes allowed dephosphorylation and nuclear translocation of CRTC2 and increased CREB-dependent
transcription of RANKL [72]. In addition to the production of RANKL, osteocytes also produce sclerostin via
MEF2-dependent transcription [75], which negatively regulates bone formation [71]. When SIK2 activity is
inhibited by PTH1 receptor-mediated PKA activation, this allows the dephosphorylation and nuclear transloca-
tion of HDAC4 and HDAC5, which inhibit MEF2 (Figure 2) to prevent the expression of sclerostin [72].
Through this mechanism, the inhibition of SIK2 in osteocytes promotes bone formation by tipping the balance
of gene expression towards CREB-dependent rather than MEF2-dependent transcription. Using osteoblast and
osteocyte-specific conditional KO models, the SIK2/3 double KO mouse was found to have increased bone
mass and accelerated bone turnover, but this was not seen in SIK1, 2 or 3 single KO, SIK1/2 double KO or
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SIK1/3 double KO mice. This increase in bone mass was prevented by combining the HDAC4/5 double KO
and SIK2/3 double KO in osteoblasts and osteocytes, indicating that HDAC4/5 may be key substrates driving
the SIK2/3 KO phenotype [76]. Consistent with this finding, treatment of osteocytes in vitro with the pan-SIK
inhibitor YKL-05-099 induced substantial changes in the gene expression profile which overlapped with that
induced by PTH signalling, including up-regulation of RANKL and suppression of sclerostin expression [72].
Moreover, treatment of adult mice with YKL-05-099 promoted bone formation and increased bone mass [72],
indicating the therapeutic potential of SIK inhibitors for the treatment of osteoporosis. Taken together, these
studies establish that SIK inhibition is central to PTH1 receptor action in bone development and remodelling.
The importance of SIK3 in bone development was first highlighted by the small size and skeletal defects
identified in SIK3 KO mice [77] and kinase-inactive SIK3[Thr163Ala] knock-in mice [15]. SIK3 KO mice dis-
played growth plate defects associated with a delay in chondrocyte differentiation (hypertrophy) and bone for-
mation [77]. Moreover, human patients expressing SIK3[Arg129Cys], a mutation that reduces SIK3 kinase
activity in vitro, have similar skeletal defects [78]. Although chondrocyte hypertrophy was delayed in mice with
a chondrocyte-specific KO of SIK3 (cKO mice), SIK1 or SIK2 partially compensated for the absence of SIK3, as
chondrocyte hypertrophy was delayed further in SIK1/3 or SIK2/3 double cKO mice [76]. Shorter proliferating
chondrocyte regions were observed at birth when the hdac4 gene was deleted in the SIK3 cKO mouse, support-
ing the idea that HDAC4 may act downstream of SIK3 to delay chondrocyte hypertrophy. In addition, the
delayed chondrocyte hypertrophy observed in the SIK3 cKO mice was completely abrogated when the hdac4
gene was deleted in the SIK3 cKO mice [76]. This suggests, but does not prove, that chondrocyte development
is regulated by the SIK3-mediated phosphorylation of HDAC4 and its translocation to the cytosol. To establish
whether this hypothesis is correct it will be necessary to also show that the delayed chondrocyte hypertrophy in
SIK3 cKO mice is mimicked by replacing wild-type HDAC4 with the HDAC4[Ser246Ala/Ser467Ala] mutant in
chondrocytes. This is because the SIK-catalysed phosphorylation of these residues appears to drive the nuclear
exit of HDAC4 enabling MEF2 and/or Runt-related transcription factor 2-dependent gene transcription to
occur (Figure 2 and Table 2) [31,79,80].
To further investigate the role of SIK3 in chondrocytes of adult mice, tamoxifen-induced SIK3 cKO mice
were studied. These experiments showed an increase in both growth plate cartilage and articular cartilage
which lubricates the ends of bones [81]. In osteoarthritis, articular cartilage chondrocytes undergo hypertrophy
comparable to the terminal differentiation of growth plate chondrocytes [82]. As SIK3 deficiency delayed chon-
drocyte hypertrophy it was suggested that the KO or inhibition of SIK3 may protect against osteoarthritis.
Indeed, there was thickening of the articular cartilage in adult SIK3 cKO mice due to increased chondrocyte
proliferation and these mice were protected from developing osteoarthritis [81]. It has been reported that the
intra-articular injection of mice with Pterosin B (Figure 3) protected against osteoarthritis [81] and based on
experiments in primary chondrocytes the mechanism was suggested to involve the PKA-dependent inhibition
of SIK3 followed by its proteasomal degradation [81,83]. It will clearly be of interest to investigate whether
pan-SIK, or SIK3-specific inhibitors protect against osteoarthritis in mouse models of this disease.
The role of SIKs in regulating circadian behaviour
Within the brain, important roles for the SIKs in regulating circadian rhythms and sleep have been uncovered.
The suprachiasmatic nuclei (SCN) is the master regulator of physiological (24 h) cycles within the body, which
co-ordinate sleep/wake timing, feeding and levels of activity, and regulate aspects of both physiology and behav-
iour. Circadian rhythms within cells are regulated by a series of negative feedback loops, for example the tran-
scription factors CLOCK and brain/muscle ARNT-like protein 1 (BMAL1) are positive regulators of
transcription, activated during the day, which drive the expression of the negative regulators Period (PER1,
PER2 and PER3) and Cryptochrome. During the morning, BMAL1 and CLOCK levels increase, and drive the
expression of PER, which accumulates during the evening and suppresses the activity of BMAL1 and CLOCK,
blocking the continued transcription of PER and Cryptochrome. Meanwhile PER and Cryptochrome proteins
are degraded, resetting the molecular clock overnight [84]. These circadian rhythms are adjusted in response to
light exposure via the retina, re-aligning the system to changes in the light/dark cycle.
Both sik1 and per1 are targets of CREB-dependent gene transcription. However, as SIK1 prevents the activa-
tion of CREB by phosphorylating CRTC1 (Figure 2), this appears to be a feedback control mechanism for
restricting the extent of CREB activation. Consistent with this notion, the siRNA-mediated knock-down of
SIK1 in NIH3T3 cells allows the continued transcription and accumulation of PER1 [8], which mediates the
adjustment of the circadian cycle to light [85]. When mice were exposed to light for 60 min during the dark
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1386








K user on 19 April 2021
phase, CREB-dependent gene transcription was activated inducing the transcription of sik1 in the SCN. The
siRNA knock-down of SIK1 in the SCN allowed an enhanced rate of adjustment to light when the light phase
of the light/dark cycle was advanced, mimicking the effect of jet lag [8].
SIK3 KO mice also demonstrated abnormalities in circadian rhythm, but in contrast with SIK1 knock-down,
this included a delay in adjustment to a shift in the light/dark cycle and a 6 h phase shift in circadian-regulated
behaviours. The overexpression of SIK3, but not the kinase-inactive SIK3[Lys37Met] mutant, promoted phos-
phorylation and degradation of PER2 in NIH3T3 cells and, conversely, PER2 levels were elevated in liver and
fibroblast cells from SIK3 KO mice. Thus the periodicity of circadian rhythms becomes dysregulated in SIK3
KO mice and cells from the SCN of these mice become rapidly desynchronised when they are cultured in the
absence of additional inputs [86]. This is reminiscent of findings in Drosophila in which SIK3 was identified as
a regulator of circadian behaviours in an RNAi screen, and SIK3 knock-down in Drosophila neurons disrupted
circadian rhythms and the cycling of PER proteins in a non-cell-autonomous manner [87].
The role of SIKs in sleep/wake regulation
Sleep/wake regulation occurs across many regions of the brain and not just the SCN. There are two compo-
nents that drive sleep/wake cycles. First, sleep need which accumulates while an animal is awake and then dissi-
pates during sleep; second, sleep latency or alertness, which is controlled by the activity of the circadian clock
[88]. The introduction of random point mutations into mice identified a strain in which sleep time driven by
increased sleep need was prolonged significantly. This increased sleep need was caused by a splice mutation
resulting from a single nucleotide substitution in the splice donor site of intron 13 of the sik3 gene, generating
the SIK3Slp/+ mice in which exon 13 is deleted [89]. Comparison of the SIK3Slp/+ mice as a model of increased
sleep need with a sleep deprivation model allowed the identification of 80 proteins in the brain whose phos-
phorylation increased with sleep need and decreased with a reduction in sleep need. A subset of these proteins
in brain extracts co-precipitated preferentially with mutant SIK3 compared with wild-type SIK3 [90].
Intracerebroventricular injection of the pan-SIK inhibitor HG-9-91-01 reduced the phosphorylation of
sleep-need-index-phosphoproteins (SNIPPs), and reduced sleep need in both sleep-deprived wild-type mice
and SIK3Slp/+ mice as indicated by reduced slow-wave activity during non-rapid-eye movement sleep [90]. The
sik3Slp mutation results in skipping of exon 13, which encodes a sequence of 52 amino acids in the C terminal
tail of SIK3 and includes the PKA-dependent phosphorylation site Ser493 (equivalent to Ser551 in human
SIK3) (Figure 1A and Table 1) [26,30,89]. Indeed, the Sleepy phenotype of increased sleep need was also seen
in mice heterozygous for the SIK3[Ser493Ala] or the SIK3[Ser493Asp] mutation [91]. Loss of this inhibitory
PKA-dependent phosphorylation site prevented 14-3-3 binding and inhibition of SIK3 [91] but did not
increase intrinsic SIK3 kinase activity [90]. This is consistent with the notion that sustained SIK3 catalytic
activity drives sleep need via phosphorylation of the SNIPPs. Loss of the PKA-dependent phosphorylation site
in SIK1 (Ser577Ala, equivalent to Ser575 in humans) or SIK2 (Ser587Ala) also increased sleep need, but less
markedly than in the SIK3 mutant mouse (Figure 1A and Table 1) [92].
Comparable effects have also been detected following SIK3 mutation in Drosophila [89] and following
KIN-29 mutation in C.elegans [89,93]. The deletion of the catalytic domain of the SIK2 orthologue in C.elegans
(KIN-29) (see Evolution of the SIKs) induced sleep defects [12]. However, kin-29 deletion also decreased cellu-
lar ATP levels despite high adipose stores, indicating a failure to regulate metabolism. Whilst KIN-29 was
required for sleep in satiated animals [94], sleep defects in C.elegans with kin-29 deletion could be overcome by
mobilising triglycerides from fat stores or by re-expressing kin-29 in a subset of sensory neurons, which also
corrected the fat phenotype [93]. Importantly, kin-29 hda-4 double mutants had normalised sleep patterns and
ATP levels [93]. Thus sleep defects in C. elegans caused by loss of SIK signalling correlated with energy deficits
in the sensory neurons, indicating a close relationship between sleep need, detection of energy requirements
and the response of fat-storage cells [93]. Further studies are needed to investigate if the regulation of sleep
need by SIK3 occurs independently of metabolism in humans, and if the SIK-HDAC signalling pathway and
alterations in metabolism are involved.
The role of SIKs in depression
The SIKs have a role in the hippocampus in regulating depression. The underlying molecular mechanism of
depression is not understood, but the activation of CREB, which drives the expression of brain-derived neuro-
trophic factor (BDNF) to promote neuronal survival and other growth factors that promote neurogenesis, is a
core signalling pathway that is suppressed in mouse models of depression and up-regulated in response to anti-
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depressants [95,96]. Increased CREB activity in the hippocampus through CREB overexpression induced anti-
depressant activity [97] and all major classes of anti-depressants increase CREB expression and activity in mul-
tiple regions of the brain including the hippocampus [95,98,99]. Hippocampal SIK2 has been reported to be
up-regulated and CRTC1-CREB signalling suppressed in two different mouse models of depression (chronic
social defeat stress (CSDS) and chronic unpredictable mild stress (CUMS)). Moreover, the overexpression of
SIK2 in the hippocampus of mice induced depressive-like behaviour, while the knock-down or KO of SIK2 in
the hippocampus prevented mice from displaying such behaviour when challenged with either the CUMS or
CSDS models of depression [100]. Furthermore, the pan-SIK inhibitor ARN-3236, which crosses the blood-
brain barrier when administered by intraperitoneal injection, induced anti-depressant effects in both models of
depression [101]. Similar protection was observed when ARN-3236 was administered via stereotactic infusion
into the hippocampus to reduce the possibility that SIK inhibition in the periphery mediates these effects [101].
Protection against CSDS or CUMS was associated with increased expression of BDNF driven by CRTC1-CREB
dependent transcription [100,101].
The role of SIKs in epilepsy
Genetic analysis of patients with developmental epilepsy identified six unrelated children with mutations in
SIK1, but no previously identified genetic markers known to associate with epilepsy. Patients were identified
with one of the following heterozygous SIK1 mutations; Pro287Thr, Ser411Cys, Gly636Ser or the truncation
mutants Glu347X, Gln614X and Gln633X (where X indicates that the SIK1 sequence terminated at this
residue). In all of the truncation mutants a stop codon was introduced C-terminal to the UBA domain in SIK1,
leaving the UBA and kinase domains intact (Figure 1A). Indeed all of these SIK1 mutants retained their kinase
activity as determined using in vitro kinase assays. On the other hand, the truncation mutants all displayed
increased stability and increased cytoplasmic localisation compared with wild-type SIK1 [102]. As a result of
multiple SIK1 mutations being identified in patients, a new subset of developmental epilepsy has been identi-
fied and termed SIK1 syndrome [103].
The role of SIKs in regulating melanin production in the skin
The determination of skin pigmentation has two components, a genetically determined constitutive factor, and
an adaptive component that produces changes in response to environmental stimuli. The presence of eumela-
nin (dark melanin) is a predictor of low skin cancer risk in response to UV irradiation [104] and therefore
modulation of the adaptive component of skin pigmentation in the absence of harmful stimuli is potentially an
attractive approach to protect against skin cancer. During UV-induced tanning, DNA damage induces the
p53-mediated expression of proopiomelanocortin (POMC) in melanocytes and keratinocytes, which is then
cleaved proteolytically to produce α-melanocyte stimulating hormone (α-MSH). The α-MSH is secreted and
binds to the melanocortin 1 receptor (MC1R) on melanocytes. Ligation of the Gαs-coupled G protein receptor
MC1R triggers the activation of adenylyl cyclase and elevation of the intracellular level of cyclic AMP, activat-
ing PKA. It was suggested that PKA phosphorylates CREB at Ser133 stimulating the transcription of
CREB-dependent genes, such as microphthalmia-associated transcription factor (MITF), which drives melano-
genesis [105]. In addition, PKA may inactivate one or more SIKs leading to the dephosphorylation and nuclear
translocation of CRTCs (Figure 2), thereby activating CREB by a second mechanism. The evidence presented
below indicates that the latter pathway may be the more significant. Elevation of cyclic AMP levels therefore
results in the production of eumelanin, while at lower cyclic AMP levels it is mainly pheomelanin (yellow-red
melanin) that is produced [105]. The human MC1R locus contains polymorphisms, with non-functional
MC1R mutants associated with red-haired, fair-skin individuals, a poor tanning response and increased risk of
developing skin cancers [104,106,107].
All three SIKs are expressed in melanocytes, but SIK2 appears to be the predominant isoform. In mouse B16
melanocytes siRNA-mediated knock-down of SIK2 induced the expression of CREB-dependent genes, includ-
ing MITF, and melanogenesis in the absence of an extracellular stimulus [108]. This indicated that melanocytes
may be primed for melanogenesis but this is restrained by the activity of SIK2. When melanocytes were
exposed to UV irradiation, CRTC1 was rapidly translocated into the nucleus, promoting CREB-dependent gene
transcription (Figure 2) and melanogenesis, an effect that was blocked by the overexpression of SIK2. When
melanocytes were stimulated in vitro with forskolin, to activate PKA in the absence of UV irradiation, tran-
scription of the MITF-dependent gene tyrosinase was blocked by the over-expression of wild type SIK2 or the
SIK2[Ser587Ala] mutant (Figure 1A), but not by the kinase-inactive SIK2[Lys49Met] mutant [108]. Consistent
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with these findings, an increase in MITF and MITF-dependent gene transcription was also detected when mel-
anocytes were treated in vitro with the pan-SIK inhibitor HG-9-91-01 [56].
Hair pigmentation in yellow-haired mice, which have an inactivating MC1R mutation, can be induced by
subcutaneous injection of forskolin, which by-passes the requirement of α-MSH-MC1R signalling to increase
intracellular cyclic AMP levels [108]. When the inactivating MC1R mutation was combined with SIK2 KO,
these mice had brown (agouti-like) hair in the absence of forskolin injection [108]. While UV irradiation was
unable to induce skin pigmentation in mice with the inactivating MC1R mutation, MC1Re/e, topical application
of forskolin rescued eumelanin production and protected mice against UV-mediated cutaneous damage [109].
Similar results were obtained when the pan-SIK inhibitor HG-9-91-01 was applied topically to MC1Re/e mice
causing darker skin pigmentation without an additional stimulus, which was reversed when the treatment was
stopped [56]. Moreover, the HG-9-91-01 derivatives YKL-06-061 and YKL-06-062 (Figure 3), which permeate
human skin more efficiently, induced skin pigmentation when tested on human skin explants [56].
Melanin is produced in melanocytes, packaged into melanosomes and then transferred to keratinocytes
[105]. Importantly, while SIK inhibitors increased the synthesis of eumelanin, they also stimulated the transfer
of melanosomes into keratinocytes [56]. This raises the possibility that skin pigmentation could be induced by
application of an SIK2 or a pan-SIK inhibitor in the absence of UV irradiation, and thus could be beneficial in
protection against the skin damage and skin cancer induced by UV irradiation.
Topical treatment with forskolin also protected against UV-induced carcinogenesis when the MC1Re/e mice
were bred with UV-sensitive xeroderma-pigmentosum-complementation-group-C-deficient mice [109].
However, whether topical application of an SIK inhibitor would also protect these mice against UV-induced
carcinogenesis, or whether there are additional benefits from forskolin treatment that are SIK-independent, has
yet to be determined. The levels of SIK2 mRNA and protein were both decreased when mouse B16 melano-
cytes were subjected to UV irradiation [108], raising the possibility that this could be one of the mechanisms
by which exposure to sun induces tanning.
The role of SIKs in regulating metabolism
The coupling of feeding/fasting states to hepatic gluconeogenesis is regulated by the circulating levels of
insulin and glucagon released by the pancreas. During prolonged fasting, glucagon up-regulates gluconeogen-
esis in hepatocytes, while in the fed state insulin inhibits the transcription of genes required for gluconeogen-
esis, such as those encoding glucose-6-phosphatase and phosphoenolpyruvate carboxykinase. Through the
phosphorylation of CRTCs and Class 2a HDAC family members (Figure 2 and Table 2), SIKs keep the gluco-
neogenic programme repressed in the fed state [110], while insulin signalling via the activation of protein
kinase B (PKB, also called AKT) represses the transcription of genes encoding gluconeogenic enzymes via the
phosphorylation and inhibition of the FOXO family of transcription factors [111]. Under fasting conditions,
the glucagon-stimulated increase in intracellular cyclic AMP activates PKA [112], which leads to the phos-
phorylation and inhibition of the SIKs (Figure 1A and Table 1) [30]. SIK inhibition in turn induces the
dephosphorylation of CRTCs which translocate to the nucleus to promote CREB-dependent transcription
(Figure 2) [9,28,113]. In parallel, Class 2a HDACs also undergo de-phosphorylation and translocation to the
nucleus (Figure 2). In the nucleus HDAC4/5 are thought to recruit HDAC3 to deacetylate and activate FOXO
family members, and together with CREB, permit transcription of the genes encoding gluconeogenic enzymes
[114,115].
The initial genetic evidence of a role for AMPK-related kinase family members in gluconeogenesis came
from studies in mice with a liver-specific KO of LKB1. These mice displayed increased fasting hyperglycaemia
and increased translocation of CRTC2 to the nucleus. The fasting blood glucose levels in these mice could be
reduced by the shRNA knock-down of CRTC2 [116]. Importantly, CRTC2 phosphorylation and blood glucose
levels were unaffected in mice with a liver-specific KO of the genes encoding both AMPKα1 and AMPKα2
[117], indicating that an LKB1-dependent, but AMPK-independent, pathway had a critical role in regulating
hepatic gluconeogenesis. When primary mouse hepatocytes were treated with the pan-SIK inhibitor
HG-9-91-01 this compound induced expression of gluconeogenic genes and increased glucose production.
These effects were due to inhibition of the SIKs, and not to an off-target effect of the inhibitor, since the over-
expression of an SIK2 mutant resistant to HG-9-91-01 prevented the effects of this compound [28]. The SIKs
have therefore been proposed as a therapeutic target for the treatment of hypoglycaemia, since their inhibition
induces gluconeogenesis [28]. Conversely, the overexpression of either SIK1 or SIK2 in the livers of diabetic
mice is sufficient to normalise blood glucose levels [9].
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It is still unclear which SIK isoforms are critical for the regulation of gluconeogenesis. No effects on hepatic
gluconeogenesis were detected in mice with a liver-specific KO of SIK1 or SIK2, but mice in which both SIK1
and SIK2 were ablated or replaced by kinase-inactive mutants were not studied [28,118]. Primary hepatocytes
from SIK3 KO mice that had not been stimulated with glucagon displayed increased expression of gluconeogenic
enzymes and more extensive dephosphorylation of CRTC2 than wild type hepatocytes, which was not observed
in SIK1 KO or SIK2 KO hepatocytes [83]. This suggests an important role for SIK3 in repressing gluconeogenesis
in the fed state. However, unexpectedly, mice in which the gene encoding SIK3 was ablated in all cells were hypo-
glycaemic [119]. However, these mice are born at sub-Mendelian frequencies and have an adverse phenotype
[77,119]. It may therefore be better to study the role of SIKs in blood glucose homeostasis using the more specific
SIK inhibitors that are becoming available in conjunction with liver-specific KO of SIK3.
It has also been reported that PKB catalyses the phosphorylation of SIK2 at Ser358 in hepatocytes and that
this underlies the insulin-induced suppression of gluconeogenesis [113]. In contrast, another study reported
that insulin induced the phosphorylation of SIK2 at Ser587 in brown adipocytes [120]. However, a further
laboratory failed to detect any insulin-induced phosphorylation of SIK2 at Ser358 and instead found that
Ser358 was only phosphorylated in hepatocytes in response to glucagon. Moreover, the liver-specific ablation of
SIK2 had no effect on the insulin-mediated suppression of gluconeogenesis [28]. Other investigators also failed
to detect any insulin-induced phosphorylation of SIK2 in 3T3L1 adipocytes, even though PKB was phosphory-
lated at a site that induces its activation. They also only observed phosphorylation of SIK2 at Ser358 in response
to cyclic AMP elevation [27]. It is therefore unlikely that SIK2, or other SIKs, are regulated by insulin or PKB.
The SIKs have been proposed to regulate the insulin response in adipocytes by controlling glucose uptake
and the transcription of lipogenic genes. Studies with human and rat adipocytes have mostly focused on SIK2,
as it is the most abundant SIK isoform in adipocytes [5,121]. SIK2 KO mice displayed increased serum levels of
triglycerides and adiponectin [122] and CRTC2, CRTC3 and HDAC4 were phosphorylated by SIK2 in rodent
and human adipocytes (Table 2) [44]. SIK2 knock-down using siRNA or adipocytes from SIK2 KO mice
reduced expression of the GLUT4 glucose transporter, whereas siRNA knock-down of CRTC2 or HDAC4 ele-
vated GLUT4 expression in rodent adipocytes [44]. However, the inhibition of SIKs with HG-9-91-01 did not
suppress GLUT4 expression in human adipocytes, although glucose uptake was reduced [11]. Therefore, more
investigation is needed to establish how SIKs regulate glucose uptake and lipogenesis in adipocytes and which
substrates mediate these effects [110].
The role of SIKs in tumorigenesis
LKB1 is a tumour suppressor and many cancer cells lack LKB1 expression. Consequently, these cancer cells are
also deficient in AMPK-related kinase activity, including all three SIKs. This raises the question of whether one
or more SIK isoforms mediate some or all of the tumour suppressive effects of LKB1. In non-small cell lung
cancer models driven by the KRAS[Gly12Asp] mutation, the tumour suppressive activity of LKB1 has been
reported to be dependent on SIK1 and SIK3. In these studies, lentivirus was used to deliver Cre-recombinase to
drive the expression of KRAS[Gly12Asp] whilst simultaneously delivering CRISPR guides to disrupt SIK1 and
SIK3 expression, which accelerated tumour growth. Similar results were obtained using Cre-recombinase to
simultaneously drive the expression of KRAS[Gly12Asp] and knock-out SIK1, alongside CRISPR-mediated
SIK3 disruption. The tumour size and neutrophil infiltration in these models of SIK1/3 disruption were com-
parable to those seen when LKB1 was knocked out alongside the expression of KRAS[Gly12Asp] [123,124].
SIKs have also been reported to act as tumour suppressors in G-protein αs-driven pancreatic tumorigenesis,
where oncogenic mutations in G-protein αs elevate intracellular cyclic AMP, and cause sustained inhibition of
SIKs, thereby modulating lipid metabolism and tumorigenesis [125]. However, SIK isoforms appear to have
both tumour suppressive and oncogenic functions dependent on the tumour type, as discussed in detail else-
where [126]. Notably, the SIK inhibitor YKL-05-099 attenuated disease progression in two acute myeloid leu-
kaemia (AML) mouse models, which was attributed to on-target inhibition of SIK3 based on overexpression of
the SIK3 gatekeeper mutant in AML cells (Figure 1C) [127]. Similarly, the SIK inhibitor ARN-3236 sensitised
ovarian cancer cells to paclitaxel treatment in a xenograft model [128]. In summary, the potential of SIK inhibi-
tors as anti-cancer agents is likely to be limited to particular types of cancer.
SIK-inhibiting drugs for the treatment of disease
It should be apparent from the preceding sections that the SIKs not only have many physiological roles
(Figure 4), but also that their inhibition could potentially be useful for the treatment of a number of diseases
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and conditions. One obvious area in which SIK inhibition may be beneficial is in the treatment of inflamma-
tory diseases, since SIK inhibitors can switch macrophages from a pro-inflammatory to an anti-inflammatory
state [17,64,65]. Indeed, the administration of anti-inflammatory macrophages to mice has been shown to
attenuate LPS-induced endotoxic shock [129,130]. SIK inhibitors may also suppress other aberrant inflamma-
tory responses driven by myeloid cells, such as those seen in rheumatoid arthritis, psoriatic arthritis and psoria-
sis, or in inflammatory bowel diseases where inflammatory myeloid cells are recruited to the gut and drive the
production of inflammatory cytokines [55,131–133]. Since SIK inhibition suppresses the secretion of inflamma-
tory cytokines and chemokines in mast cells [54], SIK-inhibiting drugs may also prove beneficial for the treat-
ment of mast cell driven diseases, including asthma. However, as the normal function of cytokines is to
co-ordinate the clearance of pathogens, the possibility that SIK-inhibiting drugs will increase the risk of micro-
bial infection cannot be discounted. Therefore, as with other anti-inflammatory drugs, it will be important to
assess whether the benefit outweighs the risk.
Apart from their potential to treat inflammatory diseases, SIK-inhibiting drugs may also have utility in the
treatment of osteoporosis, due to the ability of SIK inhibitors to promote increases in bone mass by mimicking
the effects of parathyroid hormone [72]. In addition, the topical application of SIK inhibitors could be beneficial
in protection against skin damage and skin cancer induced by UV irradiation [56]. The discovery that two inhibi-
tors of the Abelson tyrosine kinase, Dasatinib and Bosutinib, which have been approved for the treatment of
chronic myelogenous leukaemia, are potent SIK inhibitors and that the anti-inflammatory properties of Dasatinib
are likely to be attributable to SIK inhibition [58] has been encouraging, because it has provided reassurance that
targeting the SIKs in vivo can be tolerated. For the above-mentioned reasons, it is not surprising that biotechnol-
ogy companies have begun to focus on developing SIK-inhibiting drugs. On October 27th 2020, the pharmaceut-
ical company Galapagos revealed that their Toledo programme to develop drugs to treat inflammatory and
autoimmune diseases is focused on the development of SIK inhibitors (www.globenewswire.com/news-release/
2020/10/27/2115341/0/en/Galapagos-R-D-Roundtable-showcases-Toledo-program.html). They announced that
their dual SIK2/SIK3-selective inhibitor GLPG3970 had been well-tolerated in Phase I clinical trials and that it
had entered Phase 2 for ulcerative colitis, rheumatoid arthritis and primary Sjögren syndrome, and Phase 1 trials
for psoriasis and systemic lupus erythematosus. Another SIK inhibitor, GLPG4399, is currently in Phase 1 trials
(clinicaltrials.gov). In addition, they mentioned that SIK inhibitors had shown promising pre-clinical activity in
models of fibrotic disease, an area of unmet medical need. The biotechnology company, Soltego (www.soltego.
com) is also focusing on developing SIK-inhibiting drugs but, in this case, on compounds that mimic the effects
Figure 4. Physiological roles of different SIK isoforms identified by genetic analysis.
The contribution of individual SIK isoforms to the regulation of physiological processes identified by the use of knock-out and/
or knock-in mice. The major SIK isoform/s responsible for each role is colour coded; SIK1 (red), SIK2 (blue), SIK3 (green),
SIK2 and SIK3 (purple). (SIKs) The SIKs have a role in modulating gluconeogenesis in mouse hepatocytes, but which SIK
isoform(s) is responsible is unknown. In humans, mutations in SIK1 have been identified in patients with early-onset epilepsy.
Consistent with the role in bone formation, a point mutation in SIK3 has been identified in a human patient with skeletal
defects.
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of sunlight and make the skin tan without exposure to the damaging effects of UV radiation. This may help to
reduce skin cancer and even slow down the effects of ageing on the skin. The results of more advanced trials are
awaited with interest.
Outstanding questions
Although considerable progress has been made in recent years in understanding some of the physiological roles
of the SIK isoforms and how they are regulated, several important outstanding questions have yet to be
adequately addressed including the following:
1. Why are the genes encoding SIK2 and SIK3 situated so close to one another on the same chromosome and
why has this been conserved throughout vertebrate evolution? Does this proximity permit co-ordinated
transcriptional regulation of SIK2 and SIK3, or does it have some other function?
2. How are the SIK isoforms inhibited by PKA-dependent phosphorylation? Does their inhibition require the
interaction of the phosphorylated proteins with 14-3-3s?
3. What are the roles of the long C-terminal domains of the three SIKs, which have no amino acid sequence
similarities to one another and contain no recognisable structural domain? Will it be possible to crystallise
the SIKs and solve their structures, to facilitate understanding of the functions of the C-terminal region and
the UBA domain?
4. Currently, the CRTCs and the Class 2a HDACs are the only well-documented physiological substrates of
the SIKs. Do many additional substrates remain to be discovered, which can explain why the SIKs are able
to regulate the transcription of so many genes? For example, do the SIKs regulate other transcriptional
co-activators and not just CRTCs? If SIKs prevent the deacetylation of transcription factors by driving the
nuclear exit of Class 2a HDACs, do they also phosphorylate and activate the protein acetyl transferases that
oppose HDAC action?
5. What are the identities of the protein phosphatases that dephosphorylate the threonine residue in the activa-
tion loops of SIKs (Figure 1B) that are required for activity? What are the phosphatases that reactivate the
SIKs by dephosphorylating the sites targeted by PKA (Figure 1A), and which protein phosphatases depho-
sphorylate the substrates of the SIKs? Although SIK2 was reported to associate with protein phosphatase 2A
(PP2A) [34,134] there are many PP2A complexes in which the catalytic subunits, PP2Aα and PP2Aβ, interact
with different regulatory subunits that also direct subcellular location and determine substrate specificity.
Which form(s) of PP2A interacts with each SIK isoform and what is the significance of the observation that
the association of SIK2 with PP2A blocks the association of the latter with protein phosphatase
methylesterase-1, an enzyme that methylates the C-terminal carboxylate of the PP2A catalytic subunits [134]?
Undoubtedly, these and other interesting questions about the SIKs and their regulation will provide fertile areas
for future research.
Competing Interests
The authors declare that there are no competing interests associated with the manuscript.
Acknowledgements
Our research on SIKs is supported by a Programme Grant [MR/R021406/1] from the U.K. Medical Research
Council (to P.C.). We apologise that we were unable to cite all of the papers related to SIKs due to space
limitation.
Abbreviations
AML, acute myeloid leukaemia; AMPK, AMP-activated protein kinase; BDNF, brain-derived neurotrophic factor;
BMAL1, brain/muscle ARNT-like protein 1; BMDM, bone marrow-derived macrophages; CaMK,
calmodulin-dependent protein kinase; CaMKK, calmodulin-dependent protein kinase kinase; CCL, (C-C motif )
ligand; cKO, chondrocyte-specific knock-out; CREB, cyclic AMP-response-element binding protein; CRTC,
CREB-regulated transcriptional co-activator; CSDS, chronic social defeat stress; CUMS, chronic unpredictable
mild stress; GM-CSF, granulocyte-macrophage colony stimulating factor; GSK3, glycogen synthase kinase 3;
HDAC, histone deacetylase; IKK, IκB kinase; IL, interleukin; KO, knock-out; Lck, lymphocyte cell-specific
protein-tyrosine kinase; LKB1, liver kinase B1; LPS, lipopolysaccharide; MC1R, melanocortin 1 receptor; MEF2,
myocyte enhancer factor 2; MITF, microphthalmia-associated transcription factor; MSH, melanocyte stimulating
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1392








K user on 19 April 2021
hormone; PER, Period; PGE2, prostaglandin E2; PKA, cyclic AMP-dependent protein kinase; PKB, protein
kinase B; POMC, proopiomelanocortin; PP2A, protein phosphatase 2A; PRR, pattern recognition receptor; PTH,
parathyroid hormone; PTHrP, parathyroid hormone-related peptide; RANKL, receptor activator of NF-κB ligand;
SCN, suprachiasmatic nuclei; SIK, salt-inducible kinase; SNIPP, sleep-need-index-phosphoprotein; Src, sarcoma
kinase; UBA, ubiquitin-associated.
References
1 Hardie, D.G., Ross, F.A. and Hawley, S.A. (2012) AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13,
251–262 https://doi.org/10.1038/nrm3311
2 Rena, G., Pearson, E.R. and Sakamoto, K. (2013) Molecular mechanism of action of metformin: old or new insights? Diabetologia 56, 1898–1906
https://doi.org/10.1007/s00125-013-2991-0
3 LaMoia, T.E. and Shulman, G.I. (2021) Cellular and molecular mechanisms of metformin action. Endocr. Rev. 42, 77–96 https://doi.org/10.1210/
endrev/bnaa023
4 Wang, Z., Takemori, H., Halder, S.K., Nonaka, Y. and Okamoto, M. (1999) Cloning of a novel kinase (SIK) of the SNF1/AMPK family from high salt
diet-treated rat adrenal. FEBS Lett. 453, 135–139 https://doi.org/10.1016/S0014-5793(99)00708-5
5 Horike, N., Takemori, H., Katoh, Y., Doi, J., Min, L., Asano, T. et al. (2003) Adipose-specific expression, phosphorylation of Ser794 in insulin receptor
substrate-1, and activation in diabetic animals of salt-inducible kinase-2. J. Biol. Chem. 278, 18440–18447 https://doi.org/10.1074/jbc.M211770200
6 Katoh, Y., Takemori, H., Horike, N., Doi, J., Muraoka, M., Min, L. et al. (2004) Salt-inducible kinase (SIK) isoforms: their involvement in steroidogenesis
and adipogenesis. Mol. Cell. Endocrinol. 217, 109–112 https://doi.org/10.1016/j.mce.2003.10.016
7 Lin, X., Takemori, H., Katoh, Y., Doi, J., Horike, N., Makino, A. et al. (2001) Salt-inducible kinase is involved in the ACTH/cAMP-dependent protein
kinase signaling in Y1 mouse adrenocortical tumor cells. Mol. Endocrinol. 15, 1264–1276 https://doi.org/10.1210/mend.15.8.0675
8 Jagannath, A., Butler, R., Godinho, S.I., Couch, Y., Brown, L.A., Vasudevan, S.R. et al. (2013) The CRTC1-SIK1 pathway regulates entrainment of the
circadian clock. Cell 154, 1100–1111 https://doi.org/10.1016/j.cell.2013.08.004
9 Koo, S.H., Flechner, L., Qi, L., Zhang, X., Screaton, R.A., Jeffries, S. et al. (2005) The CREB coactivator TORC2 is a key regulator of fasting glucose
metabolism. Nature 437, 1109–1111 https://doi.org/10.1038/nature03967
10 Feldman, J.D., Vician, L., Crispino, M., Hoe, W., Baudry, M. and Herschman, H.R. (2000) The salt-inducible kinase, SIK, is induced by depolarization in
brain. J. Neurochem. 74, 2227–2238 https://doi.org/10.1046/j.1471-4159.2000.0742227.x
11 Säll, J., Pettersson, A.M., Björk, C., Henriksson, E., Wasserstrom, S., Linder, W. et al. (2017) Salt-inducible kinase 2 and -3 are downregulated in
adipose tissue from obese or insulin-resistant individuals: implications for insulin signalling and glucose uptake in human adipocytes. Diabetologia 60,
314–323 https://doi.org/10.1007/s00125-016-4141-y
12 Lanjuin, A. and Sengupta, P. (2002) Regulation of chemosensory receptor expression and sensory signaling by the KIN-29 Ser/Thr kinase. Neuron 33,
369–381 https://doi.org/10.1016/S0896-6273(02)00572-X
13 Okamoto, M., Takemori, H. and Katoh, Y. (2004) Salt-inducible kinase in steroidogenesis and adipogenesis. Trends Endocrinol. Metab. 15, 21–26
https://doi.org/10.1016/j.tem.2003.11.002
14 Lizcano, J.M., Goransson, O., Toth, R., Deak, M., Morrice, N.A., Boudeau, J. et al. (2004) LKB1 is a master kinase that activates 13 kinases of the
AMPK subfamily, including MARK/PAR-1. EMBO J. 23, 833–843 https://doi.org/10.1038/sj.emboj.7600110
15 Darling, N.J., Toth, R., Arthur, J.S. and Clark, K. (2017) Inhibition of SIK2 and SIK3 during differentiation enhances the anti-inflammatory phenotype of
macrophages. Biochem. J. 474, 521–537 https://doi.org/10.1042/BCJ20160646
16 Katoh, Y., Takemori, H., Lin, X.Z., Tamura, M., Muraoka, M., Satoh, T. et al. (2006) Silencing the constitutive active transcription factor CREB by the
LKB1-SIK signaling cascade. FEBS J. 273, 2730–2748 https://doi.org/10.1111/j.1742-4658.2006.05291.x
17 Clark, K., MacKenzie, K.F., Petkevicius, K., Kristariyanto, Y., Zhang, J., Choi, H.G. et al. (2012) Phosphorylation of CRTC3 by the salt-inducible kinases
controls the interconversion of classically activated and regulatory macrophages. Proc. Natl Acad. Sci. U.S.A. 109, 16986–16991 https://doi.org/10.
1073/pnas.1215450109
18 Hardie, D.G. (2014) AMP-activated protein kinase: a key regulator of energy balance with many roles in human disease. J. Intern. Med. 276, 543–559
https://doi.org/10.1111/joim.12268
19 Fogarty, S., Hawley, S.A., Green, K.A., Saner, N., Mustard, K.J. and Hardie, D.G. (2010) Calmodulin-dependent protein kinase kinase-beta activates
AMPK without forming a stable complex: synergistic effects of Ca2+ and AMP. Biochem. J. 426, 109–118 https://doi.org/10.1042/BJ20091372
20 Hashimoto, Y.K., Satoh, T., Okamoto, M. and Takemori, H. (2008) Importance of autophosphorylation at Ser186 in the A-loop of salt inducible kinase 1
for its sustained kinase activity. J. Cell. Biochem. 104, 1724–1739 https://doi.org/10.1002/jcb.21737
21 Fiol, C.J., Mahrenholz, A.M., Wang, Y., Roeske, R.W. and Roach, P.J. (1987) Formation of protein kinase recognition sites by covalent modification of
the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem. 262, 14042–14048
https://doi.org/10.1016/S0021-9258(18)47901-X
22 Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H. et al. (2007) The selectivity of protein kinase inhibitors: a further update.
Biochem. J. 408, 297–315 https://doi.org/10.1042/BJ20070797
23 Screaton, R.A., Conkright, M.D., Katoh, Y., Best, J.L., Canettieri, G., Jeffries, S. et al. (2004) The CREB coactivator TORC2 functions as a calcium- and
cAMP-sensitive coincidence detector. Cell 119, 61–74 https://doi.org/10.1016/j.cell.2004.09.015
24 Schaffer, B.E., Levin, R.S., Hertz, N.T., Maures, T.J., Schoof, M.L., Hollstein, P.E. et al. (2015) Identification of AMPK phosphorylation sites reveals a
network of proteins involved in cell invasion and facilitates large-scale substrate prediction. Cell Metab. 22, 907–921 https://doi.org/10.1016/j.cmet.
2015.09.009
25 Takemori, H., Katoh, Y., Horike, N., Doi, J. and Okamoto, M. (2002) ACTH-induced nucleocytoplasmic translocation of salt-inducible kinase. Implication
in the protein kinase A-activated gene transcription in mouse adrenocortical tumor cells. J. Biol. Chem. 277, 42334–42343 https://doi.org/10.1074/jbc.
M204602200
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1393








K user on 19 April 2021
26 Berggreen, C., Henriksson, E., Jones, H.A., Morrice, N. and Goransson, O. (2012) cAMP-elevation mediated by beta-adrenergic stimulation inhibits
salt-inducible kinase (SIK) 3 activity in adipocytes. Cell Signal. 24, 1863–1871 https://doi.org/10.1016/j.cellsig.2012.05.001
27 Henriksson, E., Jones, H.A., Patel, K., Peggie, M., Morrice, N., Sakamoto, K. et al. (2012) The AMPK-related kinase SIK2 is regulated by cAMP via
phosphorylation at Ser358 in adipocytes. Biochem. J. 444, 503–514 https://doi.org/10.1042/BJ20111932
28 Patel, K., Foretz, M., Marion, A., Campbell, D.G., Gourlay, R., Boudaba, N. et al. (2014) The LKB1-salt-inducible kinase pathway functions as a key
gluconeogenic suppressor in the liver. Nat. Commun. 5, 4535 https://doi.org/10.1038/ncomms5535
29 MacKenzie, K.F., Clark, K., Naqvi, S., McGuire, V.A., Nöehren, G., Kristariyanto, Y. et al. (2013) PGE2 induces macrophage IL-10 production and a
regulatory-like phenotype via a protein kinase A-SIK-CRTC3 pathway. J. Immunol. 190, 565–577 https://doi.org/10.4049/jimmunol.1202462
30 Sonntag, T., Vaughan, J.M. and Montminy, M. (2018) 14-3-3 proteins mediate inhibitory effects of cAMP on salt-inducible kinases (SIKs). FEBS J. 285,
467–480 https://doi.org/10.1111/febs.14351
31 Berdeaux, R., Goebel, N., Banaszynski, L., Takemori, H., Wandless, T., Shelton, G.D. et al. (2007) SIK1 is a class II HDAC kinase that promotes survival
of skeletal myocytes. Nat. Med. 13, 597–603 https://doi.org/10.1038/nm1573
32 Katoh, Y., Takemori, H., Doi, J. and Okamoto, M. (2002) Identification of the nuclear localization domain of salt-inducible kinase. Endocr. Res. 28,
315–318 https://doi.org/10.1081/ERC-120016802
33 Moorhead, G., Douglas, P., Morrice, N., Scarabel, M., Aitken, A. and MacKintosh, C. (1996) Phosphorylated nitrate reductase from spinach leaves is
inhibited by 14-3-3 proteins and activated by fusicoccin. Curr. Biol. 6, 1104–1113 https://doi.org/10.1016/S0960-9822(02)70677-5
34 Al-Hakim, A.K., Goransson, O., Deak, M., Toth, R., Campbell, D.G., Morrice, N.A. et al. (2005) 14-3-3 cooperates with LKB1 to regulate the activity and
localization of QSK and SIK. J. Cell Sci. 118, 5661–5673 https://doi.org/10.1242/jcs.02670
35 Sasaki, T., Takemori, H., Yagita, Y., Terasaki, Y., Uebi, T., Horike, N. et al. (2011) SIK2 is a key regulator for neuronal survival after ischemia via
TORC1-CREB. Neuron 69, 106–119 https://doi.org/10.1016/j.neuron.2010.12.004
36 Sjostrom, M., Stenstrom, K., Eneling, K., Zwiller, J., Katz, A.I., Takemori, H. et al. (2007) SIK1 is part of a cell sodium-sensing network that regulates
active sodium transport through a calcium-dependent process. Proc. Natl Acad. Sci. U.S.A. 104, 16922–16927 https://doi.org/10.1073/pnas.
0706838104
37 Oppermann, F.S., Gnad, F., Olsen, J.V., Hornberger, R., Greff, Z., Kéri, G. et al. (2009) Large-scale proteomics analysis of the human kinome. Mol. Cell.
Proteomics 8, 1751–1764 https://doi.org/10.1074/mcp.M800588-MCP200
38 Villén, J., Beausoleil, S.A., Gerber, S.A. and Gygi, S.P. (2007) Large-scale phosphorylation analysis of mouse liver. Proc. Natl Acad. Sci. U.S.A. 104,
1488–1493 https://doi.org/10.1073/pnas.0609836104
39 Zhou, H., Di Palma, S., Preisinger, C., Peng, M., Polat, A.N., Heck, A.J. et al. (2013) Toward a comprehensive characterization of a human cancer cell
phosphoproteome. J. Proteome Res. 12, 260–271 https://doi.org/10.1021/pr300630k
40 Huttlin, E.L., Jedrychowski, M.P., Elias, J.E., Goswami, T., Rad, R., Beausoleil, S.A. et al. (2010) A tissue-specific atlas of mouse protein
phosphorylation and expression. Cell 143, 1174–1189 https://doi.org/10.1016/j.cell.2010.12.001
41 Manning, G., Whyte, D.B., Martinez, R., Hunter, T. and Sudarsanam, S. (2002) The protein kinase complement of the human genome. Science 298,
1912–1934 https://doi.org/10.1126/science.1075762
42 Jaleel, M., Villa, F., Deak, M., Toth, R., Prescott, A.R., Van Aalten, D.M. et al. (2006) The ubiquitin-associated domain of AMPK-related kinases
regulates conformation and LKB1-mediated phosphorylation and activation. Biochem. J. 394, 545–555 https://doi.org/10.1042/BJ20051844
43 Altarejos, J.Y. and Montminy, M. (2011) CREB and the CRTC co-activators: sensors for hormonal and metabolic signals. Nat. Rev. Mol. Cell Biol. 12,
141–151 https://doi.org/10.1038/nrm3072
44 Henriksson, E., Sall, J., Gormand, A., Wasserstrom, S., Morrice, N.A., Fritzen, A.M. et al. (2015) SIK2 regulates CRTCs, HDAC4 and glucose uptake in
adipocytes. J. Cell Sci. 128, 472–486 https://doi.org/10.1242/jcs.153932
45 Sonntag, T., Moresco, J.J., Vaughan, J.M., Matsumura, S., Yates, III, J.R. and Montminy, M. (2017) Analysis of a cAMP regulated coactivator family
reveals an alternative phosphorylation motif for AMPK family members. PLoS ONE 12, e0173013 https://doi.org/10.1371/journal.pone.0173013
46 Luo, Q., Viste, K., Urday-Zaa, J.C., Senthil Kumar, G., Tsai, W.W., Talai, A. et al. (2012) Mechanism of CREB recognition and coactivation by the
CREB-regulated transcriptional coactivator CRTC2. Proc. Natl Acad. Sci. U.S.A. 109, 20865–20870 https://doi.org/10.1073/pnas.1219028109
47 Naqvi, S., Martin, K.J. and Arthur, J.S. (2014) CREB phosphorylation at Ser133 regulates transcription via distinct mechanisms downstream of cAMP
and MAPK signalling. Biochem. J. 458, 469–479 https://doi.org/10.1042/BJ20131115
48 van der Linden, A.M., Nolan, K.M. and Sengupta, P. (2007) KIN-29 SIK regulates chemoreceptor gene expression via an MEF2 transcription factor and a
class II HDAC. EMBO J. 26, 358–370 https://doi.org/10.1038/sj.emboj.7601479
49 Chan, J.K., Sun, L., Yang, X.J., Zhu, G. and Wu, Z. (2003) Functional characterization of an amino-terminal region of HDAC4 that possesses MEF2
binding and transcriptional repressive activity. J. Biol. Chem. 278, 23515–23521 https://doi.org/10.1074/jbc.M301922200
50 Parra, M. (2015) Class IIa HDACs: new insights into their functions in physiology and pathology. FEBS J. 282, 1736–1744 https://doi.org/10.1111/febs.13061
51 Fischle, W., Dequiedt, F., Hendzel, M.J., Guenther, M.G., Lazar, M.A., Voelter, W. et al. (2002) Enzymatic activity associated with class II HDACs is
dependent on a multiprotein complex containing HDAC3 and SMRT/N-CoR. Mol. Cell 9, 45–57 https://doi.org/10.1016/S1097-2765(01)00429-4
52 Abend, A., Shkedi, O., Fertouk, M., Caspi, L.H. and Kehat, I. (2017) Salt-inducible kinase induces cytoplasmic histone deacetylase 4 to promote
vascular calcification. EMBO Rep. 18, 1166–1185 https://doi.org/10.15252/embr.201643686
53 Clark, K., Peggie, M., Plater, L., Sorcek, R.J., Young, E.R., Madwed, J.B. et al. (2011) Novel cross-talk within the IKK family controls innate immunity.
Biochem. J. 434, 93–104 https://doi.org/10.1042/BJ20101701
54 Darling, N.J., Arthur, J.S.C. and Cohen, P. (2021) Salt-inducible kinases are required for the IL-33-dependent secretion of cytokines and chemokines in
mast cells. J. Biol. Chem. 296, 100428 https://doi.org/10.1016/j.jbc.2021.100428
55 Sundberg, T.B., Liang, Y., Wu, H., Choi, H.G., Kim, N.D., Sim, T. et al. (2016) Development of chemical probes for investigation of salt-inducible kinase
function in vivo. ACS Chem. Biol. 11, 2105–2111 https://doi.org/10.1021/acschembio.6b00217
56 Mujahid, N., Liang, Y., Murakami, R., Choi, H.G., Dobry, A.S., Wang, J. et al. (2017) A UV-independent topical small-molecule approach for melanin
production in human skin. Cell Rep. 19, 2177–2184 https://doi.org/10.1016/j.celrep.2017.05.042
57 Martin, M.W., Newcomb, J., Nunes, J.J., McGowan, D.C., Armistead, D.M., Boucher, C. et al. (2006) Novel 2-aminopyrimidine carbamates as potent and
orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity. J. Med. Chem. 49, 4981–4991 https://doi.org/10.1021/jm060435i
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1394








K user on 19 April 2021
58 Ozanne, J., Prescott, A.R. and Clark, K. (2015) The clinically approved drugs dasatinib and bosutinib induce anti-inflammatory macrophages by inhibiting
the salt-inducible kinases. Biochem. J. 465, 271–279 https://doi.org/10.1042/BJ20141165
59 Mosser, D.M. and Edwards, J.P. (2008) Exploring the full spectrum of macrophage activation. Nat. Rev. Immunol. 8, 958–969 https://doi.org/10.1038/nri2448
60 Sica, A. and Mantovani, A. (2012) Macrophage plasticity and polarization: in vivo veritas. J. Clin. Invest. 122, 787–795 https://doi.org/10.1172/JCI59643
61 Barrios-Rodiles, M., Tiraloche, G. and Chadee, K. (1999) Lipopolysaccharide modulates cyclooxygenase-2 transcriptionally and posttranscriptionally in
human macrophages independently from endogenous IL-1 beta and TNF-alpha. J. Immunol. 163, 963–969 PMID:10395693
62 Takaoka, A., Yanai, H., Kondo, S., Duncan, G., Negishi, H., Mizutani, T. et al. (2005) Integral role of IRF-5 in the gene induction programme activated by
toll-like receptors. Nature 434, 243–249 https://doi.org/10.1038/nature03308
63 Luan, B., Goodarzi, M.O., Phillips, N.G., Guo, X., Chen, Y.D., Yao, J. et al. (2014) Leptin-mediated increases in catecholamine signaling reduce adipose
tissue inflammation via activation of macrophage HDAC4. Cell Metab. 19, 1058–1065 https://doi.org/10.1016/j.cmet.2014.03.024
64 Sundberg, T.B., Choi, H.G., Song, J.H., Russell, C.N., Hussain, M.M., Graham, D.B. et al. (2014) Small-molecule screening identifies inhibition of
salt-inducible kinases as a therapeutic strategy to enhance immunoregulatory functions of dendritic cells. Proc. Natl Acad. Sci. U.S.A. 111,
12468–12473 https://doi.org/10.1073/pnas.1412308111
65 Lombardi, M.S., Gilliéron, C., Dietrich, D. and Gabay, C. (2016) SIK inhibition in human myeloid cells modulates TLR and IL-1R signaling and induces an
anti-inflammatory phenotype. J. Leukoc. Biol. 99, 711–721 https://doi.org/10.1189/jlb.2A0715-307R
66 Chen, L.F., Mu, Y. and Greene, W.C. (2002) Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB. EMBO J. 21,
6539–6548 https://doi.org/10.1093/emboj/cdf660
67 Chen, L., Fischle, W., Verdin, E. and Greene, W.C. (2001) Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293,
1653–1657 https://doi.org/10.1126/science.1062374
68 Kiernan, R., Brès, V., Ng, R.W., Coudart, M.P., El Messaoudi, S., Sardet, C. et al. (2003) Post-activation turn-off of NF-kappa B-dependent transcription
is regulated by acetylation of p65. J. Biol. Chem. 278, 2758–2766 https://doi.org/10.1074/jbc.M209572200
69 Quivy, V. and Van Lint, C. (2004) Regulation at multiple levels of NF-kappaB-mediated transactivation by protein acetylation. Biochem. Pharmacol. 68,
1221–1229 https://doi.org/10.1016/j.bcp.2004.05.039
70 Neer, R.M., Arnaud, C.D., Zanchetta, J.R., Prince, R., Gaich, G.A., Reginster, J.Y. et al. (2001) Effect of parathyroid hormone (1-34) on fractures and
bone mineral density in postmenopausal women with osteoporosis. N. Engl. J. Med. 344, 1434–1441 https://doi.org/10.1056/
NEJM200105103441904
71 Bonewald, L.F. (2011) The amazing osteocyte. J. Bone Miner. Res. 26, 229–238 https://doi.org/10.1002/jbmr.320
72 Wein, M.N., Liang, Y., Goransson, O., Sundberg, T.B., Wang, J., Williams, E.A. et al. (2016) SIKs control osteocyte responses to parathyroid hormone.
Nat. Commun. 7, 13176 https://doi.org/10.1038/ncomms13176
73 Fu, Q., Jilka, R.L., Manolagas, S.C. and O’Brien, C.A. (2002) Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits
osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. J. Biol. Chem. 277, 48868–48875 https://doi.org/
10.1074/jbc.M208494200
74 Xiong, J. and O’Brien, C.A. (2012) Osteocyte RANKL: new insights into the control of bone remodeling. J. Bone Miner. Res. 27, 499–505 https://doi.
org/10.1002/jbmr.1547
75 Leupin, O., Kramer, I., Collette, N.M., Loots, G.G., Natt, F., Kneissel, M. et al. (2007) Control of the SOST bone enhancer by PTH using MEF2
transcription factors. J. Bone Miner. Res. 22, 1957–1967 https://doi.org/10.1359/jbmr.070804
76 Nishimori, S., O’Meara, M.J., Castro, C.D., Noda, H., Cetinbas, M., da Silva Martins, J. et al. (2019) Salt-inducible kinases dictate parathyroid hormone
1 receptor action in bone development and remodeling. J. Clin. Invest. 129, 5187–5203 https://doi.org/10.1172/JCI130126
77 Sasagawa, S., Takemori, H., Uebi, T., Ikegami, D., Hiramatsu, K., Ikegawa, S. et al. (2012) SIK3 is essential for chondrocyte hypertrophy during skeletal
development in mice. Development 139, 1153–1163 https://doi.org/10.1242/dev.072652
78 Csukasi, F., Duran, I., Barad, M., Barta, T., Gudernova, I., Trantirek, L. et al. (2018) The PTH/PTHrP-SIK3 pathway affects skeletogenesis through altered
mTOR signaling. Sci. Transl. Med. 10, eaat9356 https://doi.org/10.1126/scitranslmed.aat9356
79 Vega, R.B., Matsuda, K., Oh, J., Barbosa, A.C., Yang, X., Meadows, E. et al. (2004) Histone deacetylase 4 controls chondrocyte hypertrophy during
skeletogenesis. Cell 119, 555–566 https://doi.org/10.1016/j.cell.2004.10.024
80 Arnold, M.A., Kim, Y., Czubryt, M.P., Phan, D., McAnally, J., Qi, X. et al. (2007) MEF2C transcription factor controls chondrocyte hypertrophy and bone
development. Dev. Cell 12, 377–389 https://doi.org/10.1016/j.devcel.2007.02.004
81 Yahara, Y., Takemori, H., Okada, M., Kosai, A., Yamashita, A., Kobayashi, T. et al. (2016) Pterosin B prevents chondrocyte hypertrophy and osteoarthritis
in mice by inhibiting Sik3. Nat. Commun. 7, 10959 https://doi.org/10.1038/ncomms10959
82 Aigner, T., Söder, S., Gebhard, P.M., McAlinden, A. and Haag, J. (2007) Mechanisms of disease: role of chondrocytes in the pathogenesis of
osteoarthritis–structure, chaos and senescence. Nat. Clin. Pract. Rheumatol. 3, 391–399 https://doi.org/10.1038/ncprheum0534
83 Itoh, Y., Sanosaka, M., Fuchino, H., Yahara, Y., Kumagai, A., Takemoto, D. et al. (2015) Salt-inducible kinase 3 signaling is important for the
gluconeogenic programs in mouse hepatocytes. J. Biol. Chem. 290, 17879–17893 https://doi.org/10.1074/jbc.M115.640821
84 Cox, K.H. and Takahashi, J.S. (2019) Circadian clock genes and the transcriptional architecture of the clock mechanism. J. Mol. Endocrinol. 63,
R93–R102 https://doi.org/10.1530/JME-19-0153
85 Albrecht, U., Sun, Z.S., Eichele, G. and Lee, C.C. (1997) A differential response of two putative mammalian circadian regulators, mper1 and mper2, to
light. Cell 91, 1055–1064 https://doi.org/10.1016/S0092-8674(00)80495-X
86 Hayasaka, N., Hirano, A., Miyoshi, Y., Tokuda, I.T., Yoshitane, H., Matsuda, J. et al. (2017) Salt-inducible kinase 3 regulates the mammalian circadian
clock by destabilizing PER2 protein. elife 6, e24779 https://doi.org/10.7554/eLife.24779
87 Fujii, S., Emery, P. and Amrein, H. (2017) SIK3-HDAC4 signaling regulates Drosophila circadian male sex drive rhythm via modulating the DN1 clock
neurons. Proc. Natl Acad. Sci. U.S.A. 114, E6669–E6677 https://doi.org/10.1073/pnas.1620483114
88 Borbély, A.A., Daan, S., Wirz-Justice, A. and Deboer, T. (2016) The two-process model of sleep regulation: a reappraisal. J. Sleep Res. 25, 131–143
https://doi.org/10.1111/jsr.12371
89 Funato, H., Miyoshi, C., Fujiyama, T., Kanda, T., Sato, M., Wang, Z. et al. (2016) Forward-genetics analysis of sleep in randomly mutagenized mice.
Nature 539, 378–383 https://doi.org/10.1038/nature20142
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1395








K user on 19 April 2021
90 Wang, Z., Ma, J., Miyoshi, C., Li, Y., Sato, M., Ogawa, Y. et al. (2018) Quantitative phosphoproteomic analysis of the molecular substrates of sleep
need. Nature 558, 435–439 https://doi.org/10.1038/s41586-018-0218-8
91 Honda, T., Fujiyama, T., Miyoshi, C., Ikkyu, A., Hotta-Hirashima, N., Kanno, S. et al. (2018) A single phosphorylation site of SIK3 regulates daily sleep
amounts and sleep need in mice. Proc. Natl Acad. Sci. U.S.A. 115, 10458–10463 https://doi.org/10.1073/pnas.1810823115
92 Park, M., Miyoshi, C., Fujiyama, T., Kakizaki, M., Ikkyu, A., Honda, T. et al. (2020) Loss of the conserved PKA sites of SIK1 and SIK2 increases sleep
need. Sci. Rep. 10, 8676 https://doi.org/10.1038/s41598-020-65647-0
93 Grubbs, J.J., Lopes, L.E., van der Linden, A.M. and Raizen, D.M. (2020) A salt-induced kinase is required for the metabolic regulation of sleep. PLoS
Biol. 18, e3000220 https://doi.org/10.1371/journal.pbio.3000220
94 van der Linden, A.M., Wiener, S., You, Y.J., Kim, K., Avery, L. and Sengupta, P. (2008) The EGL-4 PKG acts with KIN-29 salt-inducible kinase and
protein kinase A to regulate chemoreceptor gene expression and sensory behaviors in caenorhabditis elegans. Genetics 180, 1475–1491 https://doi.
org/10.1534/genetics.108.094771
95 Nestler, E.J., Barrot, M., DiLeone, R.J., Eisch, A.J., Gold, S.J. and Monteggia, L.M. (2002) Neurobiology of depression. Neuron 34, 13–25 https://doi.
org/10.1016/S0896-6273(02)00653-0
96 Krishnan, V. and Nestler, E.J. (2008) The molecular neurobiology of depression. Nature 455, 894–902 https://doi.org/10.1038/nature07455
97 Chen, A.C., Shirayama, Y., Shin, K.H., Neve, R.L. and Duman, R.S. (2001) Expression of the cAMP response element binding protein (CREB) in
hippocampus produces an antidepressant effect. Biol. Psychiatry. 49, 753–762 https://doi.org/10.1016/S0006-3223(00)01114-8
98 Nibuya, M., Nestler, E.J. and Duman, R.S. (1996) Chronic antidepressant administration increases the expression of cAMP response element binding
protein (CREB) in rat hippocampus. J. Neurosci. 16, 2365–2372 https://doi.org/10.1523/JNEUROSCI.16-07-02365.1996
99 Thome, J., Sakai, N., Shin, K., Steffen, C., Zhang, Y.J., Impey, S. et al. (2000) cAMP response element-mediated gene transcription is upregulated by
chronic antidepressant treatment. J. Neurosci. 20, 4030–4036 https://doi.org/10.1523/JNEUROSCI.20-11-04030.2000
100 Jiang, B., Wang, H., Wang, J.L., Wang, Y.J., Zhu, Q., Wang, C.N. et al. (2019) Hippocampal salt-inducible kinase 2 plays a role in depression via the
CREB-regulated transcription coactivator 1-cAMP response element binding-brain-derived neurotrophic factor pathway. Biol. Psychiatry 85, 650–666
https://doi.org/10.1016/j.biopsych.2018.10.004
101 Liu, Y., Tang, W., Ji, C., Gu, J., Chen, Y., Huang, J. et al. (2020) The selective SIK2 inhibitor ARN-3236 produces strong antidepressant-like efficacy in
mice via the hippocampal CRTC1-CREB-BDNF pathway. Front. Pharmacol. 11, 624429 https://doi.org/10.3389/fphar.2020.624429
102 Hansen, J., Snow, C., Tuttle, E., Ghoneim, D.H., Yang, C.S., Spencer, A. et al. (2015) De novo mutations in SIK1 cause a spectrum of developmental
epilepsies. Am. J. Hum. Genet. 96, 682–690 https://doi.org/10.1016/j.ajhg.2015.02.013
103 Proschel, C., Hansen, J.N., Ali, A., Tuttle, E., Lacagnina, M., Buscaglia, G. et al. (2017) Epilepsy-causing sequence variations in SIK1 disrupt synaptic
activity response gene expression and affect neuronal morphology. Eur. J. Hum. Genet. 25, 216–221 https://doi.org/10.1038/ejhg.2016.145
104 Armstrong, B.K. and Kricker, A. (2001) The epidemiology of UV induced skin cancer. J. Photochem. Photobiol. B 63, 8–18 https://doi.org/10.1016/
S1011-1344(01)00198-1
105 Lin, J.Y. and Fisher, D.E. (2007) Melanocyte biology and skin pigmentation. Nature 445, 843–850 https://doi.org/10.1038/nature05660
106 Valverde, P., Healy, E., Jackson, I., Rees, J.L. and Thody, A.J. (1995) Variants of the melanocyte-stimulating hormone receptor gene are associated with
red hair and fair skin in humans. Nat. Genet. 11, 328–330 https://doi.org/10.1038/ng1195-328
107 Scott, M.C., Wakamatsu, K., Ito, S., Kadekaro, A.L., Kobayashi, N., Groden, J. et al. (2002) Human melanocortin 1 receptor variants, receptor function
and melanocyte response to UV radiation. J. Cell Sci. 115, 2349–2355 PMID:12006619
108 Horike, N., Kumagai, A., Shimono, Y., Onishi, T., Itoh, Y., Sasaki, T. et al. (2010) Downregulation of SIK2 expression promotes the melanogenic program
in mice. Pigment Cell Melanoma Res. 23, 809–819 https://doi.org/10.1111/j.1755-148X.2010.00760.x
109 D’Orazio, J.A., Nobuhisa, T., Cui, R., Arya, M., Spry, M., Wakamatsu, K. et al. (2006) Topical drug rescue strategy and skin protection based on the role
of Mc1r in UV-induced tanning. Nature 443, 340–344 https://doi.org/10.1038/nature05098
110 Sakamoto, K., Bultot, L. and Göransson, O. (2018) The salt-inducible kinases: emerging metabolic regulators. Trends Endocrinol. Metab. 29, 827–840
https://doi.org/10.1016/j.tem.2018.09.007
111 Haeusler, R.A., Kaestner, K.H. and Accili, D. (2010) Foxos function synergistically to promote glucose production. J. Biol. Chem. 285, 35245–35248
https://doi.org/10.1074/jbc.C110.175851
112 Jiang, G. and Zhang, B.B. (2003) Glucagon and regulation of glucose metabolism. Am. J. Physiol. Endocrinol. Metab. 284, E671–E678 https://doi.org/
10.1152/ajpendo.00492.2002
113 Dentin, R., Liu, Y., Koo, S.H., Hedrick, S., Vargas, T., Heredia, J. et al. (2007) Insulin modulates gluconeogenesis by inhibition of the coactivator TORC2.
Nature 449, 366–369 https://doi.org/10.1038/nature06128
114 Mihaylova, M.M., Vasquez, D.S., Ravnskjaer, K., Denechaud, P.D., Yu, R.T., Alvarez, J.G. et al. (2011) Class IIa histone
deacetylases are hormone-activated regulators of FOXO and mammalian glucose homeostasis. Cell 145, 607–621 https://doi.org/10.1016/j.cell.2011.
03.043
115 Wang, B., Moya, N., Niessen, S., Hoover, H., Mihaylova, M.M., Shaw, R.J. et al. (2011) A hormone-dependent module regulating energy balance. Cell
145, 596–606 https://doi.org/10.1016/j.cell.2011.04.013
116 Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A. et al. (2005) The kinase LKB1 mediates glucose homeostasis in liver and
therapeutic effects of metformin. Science 310, 1642–1646 https://doi.org/10.1126/science.1120781
117 Foretz, M., Hébrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G. et al. (2010) Metformin inhibits hepatic gluconeogenesis in mice
independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120, 2355–2369 https://doi.org/10.1172/JCI40671
118 Nixon, M., Stewart-Fitzgibbon, R., Fu, J., Akhmedov, D., Rajendran, K., Mendoza-Rodriguez, M.G. et al. (2016) Skeletal muscle salt inducible kinase 1
promotes insulin resistance in obesity. Mol. Metab. 5, 34–46 https://doi.org/10.1016/j.molmet.2015.10.004
119 Uebi, T., Itoh, Y., Hatano, O., Kumagai, A., Sanosaka, M., Sasaki, T. et al. (2012) Involvement of SIK3 in glucose and lipid homeostasis in mice. PLoS
ONE 7, e37803 https://doi.org/10.1371/journal.pone.0037803
120 Muraoka, M., Fukushima, A., Viengchareun, S., Lombes, M., Kishi, F., Miyauchi, A. et al. (2009) Involvement of SIK2/TORC2 signaling cascade in the
regulation of insulin-induced PGC-1alpha and UCP-1 gene expression in brown adipocytes. Am. J. Physiol. Endocrinol. Metab. 296, E1430–E1439
https://doi.org/10.1152/ajpendo.00024.2009
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).1396








K user on 19 April 2021
121 Du, J., Chen, Q., Takemori, H. and Xu, H. (2008) SIK2 can be activated by deprivation of nutrition and it inhibits expression of lipogenic genes in
adipocytes. Obesity (Silver Spring) 16, 531–538 https://doi.org/10.1038/oby.2007.98
122 Park, J., Yoon, Y.S., Han, H.S., Kim, Y.H., Ogawa, Y., Park, K.G. et al. (2014) SIK2 is critical in the regulation of lipid homeostasis and adipogenesis in
vivo. Diabetes 63, 3659–3673 https://doi.org/10.2337/db13-1423
123 Hollstein, P.E., Eichner, L.J., Brun, S.N., Kamireddy, A., Svensson, R.U., Vera, L.I. et al. (2019) The AMPK-related kinases SIK1 and SIK3 mediate key
tumor-suppressive effects of LKB1 in NSCLC. Cancer Discov. 9, 1606–1627 https://doi.org/10.1158/2159-8290.CD-18-1261
124 Murray, C.W., Brady, J.J., Tsai, M.K., Li, C., Winters, I.P., Tang, R. et al. (2019) An LKB1-SIK axis suppresses lung tumor growth and controls
differentiation. Cancer Discov. 9, 1590–1605 https://doi.org/10.1158/2159-8290.CD-18-1237
125 Patra, K.C., Kato, Y., Mizukami, Y., Widholz, S., Boukhali, M., Revenco, I. et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing
PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat. Cell Biol. 20, 811–822 https://doi.org/10.1038/s41556-018-0122-3
126 Sun, Z., Jiang, Q., Li, J. and Guo, J. (2020) The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis. Signal.
Transduct. Target Ther. 5, 150 https://doi.org/10.1038/s41392-020-00265-w
127 Tarumoto, Y., Lin, S., Wang, J., Milazzo, J.P., Xu, Y., Lu, B. et al. (2020) Salt-inducible kinase inhibition suppresses acute myeloid leukemia progression
in vivo. Blood 135, 56–70 https://doi.org/10.1182/blood.2019001576
128 Zhou, J., Alfraidi, A., Zhang, S., Santiago-O’Farrill, J.M., Yerramreddy Reddy, V.K., Alsaadi, A. et al. (2017) A novel compound ARN-3236 inhibits
salt-inducible kinase 2 and sensitizes ovarian cancer cell lines and xenografts to paclitaxel. Clin. Cancer Res. 23, 1945–1954 https://doi.org/10.1158/
1078-0432.CCR-16-1562
129 Gerber, J.S. and Mosser, D.M. (2001) Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J. Immunol. 166,
6861–6868 https://doi.org/10.4049/jimmunol.166.11.6861
130 Fleming, B.D. and Mosser, D.M. (2011) Regulatory macrophages: setting the threshold for therapy. Eur. J. Immunol. 41, 2498–2502 https://doi.org/10.
1002/eji.201141717
131 Kopf, M., Bachmann, M.F. and Marsland, B.J. (2010) Averting inflammation by targeting the cytokine environment. Nat. Rev. Drug Discov. 9, 703–718
https://doi.org/10.1038/nrd2805
132 Shouval, D.S., Ouahed, J., Biswas, A., Goettel, J.A., Horwitz, B.H., Klein, C. et al. (2014) Interleukin 10 receptor signaling: master regulator of intestinal
mucosal homeostasis in mice and humans. Adv. Immunol. 122, 177–210 https://doi.org/10.1016/B978-0-12-800267-4.00005-5
133 Braat, H., Rottiers, P., Hommes, D.W., Huyghebaert, N., Remaut, E., Remon, J.P. et al. (2006) A phase I trial with transgenic bacteria expressing
interleukin-10 in crohn’s disease. Clin. Gastroenterol. Hepatol. 4, 754–759 https://doi.org/10.1016/j.cgh.2006.03.028
134 Lee, C.W., Yang, F.C., Chang, H.Y., Chou, H., Tan, B.C. and Lee, S.C. (2014) Interaction between salt-inducible kinase 2 and protein phosphatase 2A
regulates the activity of calcium/calmodulin-dependent protein kinase I and protein phosphatase methylesterase-1. J. Biol. Chem. 289, 21108–21119
https://doi.org/10.1074/jbc.M113.540229
135 Kemp, B.E., Graves, D.J., Benjamini, E. and Krebs, E.G. (1977) Role of multiple basic residues in determining the substrate specificity of cyclic
AMP-dependent protein kinase. J. Biol. Chem. 252, 4888–4894 https://doi.org/10.1016/S0021-9258(17)40137-2
136 Mackintosh, C. (2004) Dynamic interactions between 14-3-3 proteins and phosphoproteins regulate diverse cellular processes. Biochem. J. 381,
329–342 https://doi.org/10.1042/BJ20031332
© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 1397








K user on 19 April 2021
